Document:

<PAGE>

                                                                   EXHIBIT 10.6

                           EXCLUSIVE LICENSE AGREEMENT

      THIS LICENSE AGREEMENT is made and entered into as of this 28th day of
August, 2002 (the "Effective Date") by and between EMORY UNIVERSITY, a
non-profit Georgia corporation with offices located at 1380 South Oxford Road,
N.E., Atlanta, Georgia 30322 (hereinafter referred to as "EMORY"), and
CYBERKINETICS, INC., a for-profit Delaware corporation with offices located at
109 Hazard Avenue, Providence, RI 02906 (hereinafter referred to as
"CYBERKINETICS").

                                   WITNESSETH

      WHEREAS, EMORY is the assignee of all right, title, and interest in
certain inventions developed by an employee of EMORY and is responsible for the
protection and commercial development of such inventions; and

      WHEREAS, Donald R. Humphrey, Ph.D., is an employee of EMORY and is named
as sole inventor (hereafter referred to as the "Inventor") in United States
Patent No. * * * for * * *, and

      WHEREAS, CYBERKINETICS has the necessary expertise and will, as
appropriate, acquire the resources reasonably necessary to fully develop, obtain
approval for, and market products based upon the inventions claimed in the
above-referenced patent and the know-how not covered by the patent and licensed
hereunder; and

      WHEREAS, EMORY wants to have such inventions developed, commercialized,
and made available for use by the public; and

      WHEREAS, EMORY and CYBERKINETICS entered into that certain "Terms for
EMORY-CYBERKINETICS License Agreement" dated July 11, 2002 whereby EMORY and
CYBERKINETICS agreed to close the license between EMORY and CYBERKINETICS and a
stock purchase between EMORY and CYBERKINETICS for CYBERKINETICS to issue a
certain amount of its equity to EMORY based on the terms agreed upon therein;
and

      WHEREAS, EMORY desires to grant, and CYBERKINETICS desires to receive, an
exclusive, worldwide license to make, have made, import, use, offer to sell and
sell products based on or incorporating the inventions;

      NOW, THEREFORE, for and in consideration of the mutual covenants and the
premises herein contained, the parties, intending to be legally bound, hereby
agree as follows.

                             ARTICLE 1. DEFINITIONS

      The following terms as used herein shall have the following meaning:

      1.1   "Affiliate" shall mean any corporation or non-corporate business
entity, which controls, is controlled by, or is under common control with a
party to this Agreement. A corporation or non-corporate business entity shall be
regarded as in control of another corporation if it owns, or

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

<PAGE>

directly or indirectly controls, at least fifty (50%) percent of the voting
stock of the other corporation, or (i) in the absence of the ownership of at
least fifty (50%) percent of the voting stock of a corporation or (ii) in the
case of a non-corporate business entity, or non-profit corporation, if it
possesses, directly or indirectly, the power to direct or cause the direction of
the management and policies of such corporation or non-corporate business
entity, as applicable.

      1.2.  "Agreement" or "License Agreement" shall mean this Agreement,
including all APPENDICES attached to this Agreement.

      1.3.  "Dollars" shall mean United States dollars.

      1.4   "EMORY" shall mean EMORY University.

      1.5.  "FDA" shall mean (a) the United States Food and Drug Administration
or successor entity thereto, and (b) any other foreign agency or commission
performing comparable functions where specifically specified in this Agreement.

      1.6.  "Field of Use" shall mean all fields.

      1.7.  "Indemnitees" shall mean EMORY, its directors, employees and
students, and their heirs, executors, administrators, successors and legal
representatives.

      1.8.  "Licensed Know-How" shall mean all technical information and data,
other than the Licensed Patents, whether or not presently known or learned,
invented, or developed by the Inventor or any employees of EMORY working under
the Inventor's direct supervision, prior to the date of this agreement and while
they were under a duty to assign intellectual property rights to EMORY, to the
extent that (a) such technical information and data are useful for the
manufacture, use, importation, offer for sale or sale of any Licensed Product;
(b) EMORY possesses the right to license the use of such information and data to
CYBERKINETICS for commercial purposes without incurring financial or other
non-contingent, material obligations to any third party and without breaching
any obligations of confidentiality with any such party; and (c) such information
and data is not presently owned by CYBERKINETICS and does not in the future
become publicly known other than through disclosure by CYBERKINETICS.

      1.9.  "Licensed Patents" shall mean U.S. Patent No. * * * for "* * *"
Issued * * *, together with any and all substitutions, extensions, divisional,
continuations, continuations-in-part, which issue thereon anywhere in the world,
including reexamined and reissued patents and any extension of the term of any
such patent (including supplementary protection certificates) and all
corresponding foreign equivalents.

      1.10. "Licensed Products" shall mean any products, the manufacture, use,
importation, offer for sale or sale of which incorporate Licensed Technology, or
which would, absent the licenses granted in this Agreement, infringe any Valid
Claim included in any Licensed Patent.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       2
<PAGE>

      1.11. "Licensed Technology" shall mean the Licensed Patents and the
Licensed Know-How

      1.12. "Licensed Territory" shall mean the world.

      1.13. "Net Sales" shall mean gross amounts invoiced for "End Sales" (as
defined below) of a Licensed Product less the sum of (i) trade, quantity and
cash discounts actually allowed or paid, (ii) refunds, rebates, chargebacks,
retroactive price adjustments (including Medicaid, managed care and similar
types of rebates) and service allowances, (iii) credits or allowances given or
made for rejections or returns of previously sold products or for wastage
replacement actually taken or allowed, (iv) taxes, duties or other governmental
charges levied on or measured by the billing amount, as adjusted for rebates and
refunds, and (v) charges for shipping, freight and insurance directly related to
the distribution of the Licensed Product (excluding amounts reimbursed by third
party customers). End Sales shall mean all sales of any Licensed Product by
CYBERKINETICS, its Affiliates, or its Sublicensees other than sales ("Excluded
Sales") to CYBERKINETICS, an Affiliate or a Sublicensee, provided, however, that
End Sales shall include the sale of any Licensed Product to CYBERKINETICS, an
Affiliate or a Sublicensee where the purchaser of such Licensed Product is the
ultimate end-user of such Licensed Product and such Licensed Product is used by
such purchaser for commercial purposes to generate revenue from one or more
third parties, as opposed to use for research, development, manufacturing,
quality control, testing or similar uses in connection with the development or
commercialization of any Licensed Product. Sales of a Licensed Product for use
in conducting clinical trials of such Licensed Product in a country of the
Licensed Territory in order to obtain regulatory approval of such Licensed
Product in such country shall be included in Net Sales calculations only to the
extent that the amount included in such Net Sales exceeds the fully loaded cost
incurred by the party supplying such Licensed Product to supply such Licensed
Product.

      If a Licensed Product (a) consists of both (i) components causing such
product to be a Licensed Product and (ii) other components. or (b) is sold
together with one or more other products for a single invoiced price (e.g.,
where a product is a medical device comprised of one component that is Licensed
Product and other components that are not Licensed Products, or where a medical
device that is a Licensed Product is packaged for sale with a second medical
device that is not a Licensed Product) (each, a "Combination Sale"), the Net
Sales for such Licensed Product shall be the portion of such Combination Sale
properly allocable to such Licensed Product, determined as follows.

      Except as provided below, the Net Sales for a Licensed Product sold in
such a Combination Sale shall equal the gross amount invoiced for sale of the
Licensed Product and any and all other products or components, as the case may
be, included in such Combination Sale, reduced by the adjustments specified
above in the definition of Net Sales (the "Net Combination Sale Amount"),
multiplied by the fraction A/(A+B), where:

                  * * *
      In the event that CYBERKINETICS, its Affiliate or Sublicensee, as
applicable, separately sells the Licensed Product included in a Combination Sale
in a country, but does not separately sell

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       3
<PAGE>
all of the other products or
components, as the case may be, included in such Combination Sale in such
country, the calculation of "Net Sale" resulting from such Combination Sale
shall be determined by multiplying the Net Combination Sale Amount by the
fraction A/C where:

                  * * *
      In the event that CYBERKINETICS, its Affiliate or Sublicensee, as
applicable, does not separately sell the Licensed Product contained in a
Combination Sale in the country where such Combination Sale occurs, but does
separately sell all of the other products or components, as the case may be,
included in the Combination Sale in such country, the calculation of Net Sales
resulting from such Combination Sale shall be determined by multiplying the Net
Combination Sale Amount by the fraction (C-D)/C, where:

                  * * *

      Where the calculation of Net Sales resulting from a Combination Sale in a
country cannot be determined by any of the foregoing methods, the calculation of
Net Sales for such Combination Sale shall be * * *.

      1.14. "Person" shall mean any natural person or legal entity.

      1.15. "Regulatory Approval" or "Regulatory Registration" shall mean, in
relation to any Licensed Product, such approvals by the regulatory authorities
in a given country (including pricing approvals) as may be legally required
before such Licensed Products may be commercialized or Sold in such country.

      1.16. "Sale" or "Sold" shall mean the sale, lease, transfer, exchange, or
other disposition of Licensed Products to a third party whether by gift or
otherwise by CYBERKINETICS, its Affiliates, Sublicensees, distributors or any
third party authorized by CYBERKINETICS to make such sale, transfer, exchange or
disposition. Sales of Licensed Products shall be deemed consummated upon the
first to occur of: (a) receipt of payment from the purchaser; (b) delivery of
Licensed Products to the purchaser or a common carrier; (c) release of Licensed
Products from consignment; (d) if deemed Sold by use, when first put to such
use; or (e) if otherwise transferred, exchanged, or disposed of, whether by gift
or otherwise, when such transfer, exchange, gift, or other disposition occurs.
Notwithstanding the foregoing definition of Sale, to the extent CYBERKINETICS
distributes any Licensed Product under a treatment trial or other expanded
access program at a sales price that exceeds its fully absorbed cost therefor,
such excess shall be deemed to be a Sale for which royalties are payable in
accordance with the other terms hereof.

      1.17. "Sublicensee" shall mean any Person to whom CYBERKINETICS grants a
sublicense of some or all of the rights granted to CYBERKINETICS under this
Agreement.

      1.18. "U.S. 510 (k)" shall mean Article 510 (k) of the Food, Drug and
Cosmetic Act also known as Premarket Notification (PMN), corresponding
application or its equivalent.

      1.19. "U.S. IDE" shall mean Investigational Device Exemption,
corresponding applications or its equivalent.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       4
<PAGE>

      1.20. "U.S. Government Licenses" shall mean the non-exclusive license to
the U.S. Government directly, or acting through one of its recognized agencies.

      1.21. "Valid Claim" shall mean an issued claim of any unexpired patent or
claim of any pending patent application included among the Licensed Patents,
which has not been held unenforceable, unpatentable or invalid by a decision of
a court or governmental body of competent jurisdiction, unappealable or
unappealed within the time allowed for appeal, which has not been rendered
unenforceable through disclaimer or otherwise, which has not been donated to the
public, and which has not been lost through an interference proceeding.

                           ARTICLE 2. GRANT OF LICENSE

      2.1.  License. Subject to the terms and conditions of this Agreement,
EMORY hereby grants CYBERKINETICS and its Affiliates an exclusive,
sublicenseable, royalty-bearing license under EMORY's interests and rights in
the Licensed Technology to make, have made, use, import, offer for sale, and
sell Licensed Products in the Licensed Territory and in the Licensed Field
during the term of this Agreement.

      2.2.  Government Rights. The license granted in Article 2.1 above is
subject to the U.S. Government Licenses and other rights retained by the United
States in inventions developed by nonprofit institutions with the support of
federal funds. These rights are set forth in 35 USCA Section 201 et seq. and 37
CFR 401 et seq., which may be amended from time to time by the Congress of the
United States or through administrative procedures.

      2.3.  Retained License. The license granted in Article 2.1 above is
further subject to a right and license retained by EMORY on behalf of itself and
its Affiliates to practice the Licensed Technology for EMORY's non-commercial
research and educational purposes only; provided, however, that nothing in this
Article 2.3 shall limit in any way the Inventor's rights under the "research
exception" under common law to practice the Licensed Technology solely for
non-commercial research and educational purposes.

      2.4.  Sublicenses. CYBERKINETICS shall have the right to grant sublicenses
consistent with its diligence obligations under Article 6 hereof. CYBERKINETICS
shall notify EMORY at least twenty (20) days prior to entering into any
sublicense agreement and will provide EMORY with copies of all sublicense
agreements within ninety (90) days of their execution date. CYBERKINETICS
understands that flipping the Licensed Technology in the form of a sublicense
without adding value (i.e. without itself having first undertaken further
development activity or requiring that its Sublicensee undertake further
development activities) to the Licensed Technology is prohibited and EMORY
retains the right to disapprove such sublicensing activities. CYBERKINETICS
shall remain responsible to EMORY for the payment of all fees and royalties due
under this Agreement, whether or not such payments are made to CYBERKINETICS,
its Affiliates or its Sublicensees. CYBERKINETICS shall include in any
sublicense granted pursuant to this Agreement a provision requiring the
Sublicensee to (i) abide by the confidentiality obligations herein, (ii)
indemnify EMORY and (iii) maintain liability insurance coverage to the same
extent that CYBERKINETICS is so required pursuant to Article 10.3 of this
Agreement. CYBERKINETICS shall not grant any rights to any Sublicensee, which
are

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       5
<PAGE>

inconsistent with the rights granted to and obligations of CYBERKINETICS
hereunder. Any act or omission of a Sublicensee, which would be a breach of this
Agreement if performed by CYBERKINETICS, shall be deemed to be a breach by such
Sublicensee of its sublicense agreement.

      If this Agreement terminates for any reason, any Sublicensee shall, from
the effective date of such termination, automatically become a direct licensee
of EMORY with respect to the rights originally sublicensed to it by
CYBERKINETICS, provided such Sublicensee did not cause the termination of this
Agreement and such Sublicensee agrees to comply with all of the terms of this
Agreement and assumes the responsibilities of CYBERKINETICS hereunder to the
extent applicable from the rights originally sublicensed to it by CYBERKINETICS.

      2.5.  No Implied License. The license and rights granted in this Agreement
shall not be construed to confer any rights upon CYBERKINETICS by implication,
estoppel, or otherwise as to any technology not specifically identified in this
Agreement as Licensed Patents or Licensed Know-How.

                     ARTICLE 3. ROYALTIES AND OTHER PAYMENTS

      3.1.  Signing Fee. CYBERKINETICS shall, within thirty (30) days of
execution of the License Agreement, pay EMORY the sum of * * * as a signing fee.

      3.2.  Running Royalties for Sale of Licensed Products by CYBERKINETICS or
its Affiliates or Sublicensees. CYBERKINETICS or its Affiliates or Sublicensees
shall pay EMORY royalty equal to the Applicable Percentage of Net Sales of
Licensed Products by CYBERKINETICS, its Affiliates or Sublicensees in the
Territory. The Applicable Percentage with respect to * * *of such Net Sales in
any fiscal year of CYBERKINETICS shall be * * * and with respect to all
additional such Net Sales in any such fiscal year shall be * * *, subject to
adjustment as provided below.

            (a)   The running royalties payable under this Article 3.2 on any
Net Sales of Licensed Products shall be reduced by * * * of any royalties
payable to third parties by CYBERKINETICS, its Affiliates or its Sublicensees on
the same Net Sales of Licensed Products. Absent the written consent of EMORY,
the reduction in royalty rates specified by this subparagraph (a) shall not
operate to reduce the running royalty rates payable by CYBERKINETICS, its
Affiliates and its Sublicensees to EMORY during any fiscal year of CYBERKINETICS
to less than* * * of Net Sales of Licensed Products during such fiscal year * *
* in the case of Know-How Only Net Sales (as defined below)).

            (b)   Licensee's obligation to pay a running royalty on a Licensed
Product shall terminate upon the later of (i) * * * and (ii) * * *.

            (c)   All royalty payments due to EMORY hereunder shall be subject
to any tax withholding required under the laws of any country, and all payments
to EMORY hereunder shall be net of such taxes.

            (d)   The Applicable Percentage shall be reduced by * * * with
respect to any Net Sales with respect to any Licensed Product in a particular
country that is a Licensed Product in such

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       6
<PAGE>

country solely because such Licensed Product incorporates Licensed Know-How and
is not covered by a Valid Claim ("Know-How Only Net Sales").

      3.3.  Milestone Payments. Upon the achievement of each event set forth
below, on a Licensed Product-by-Licensed Product basis, CYBERKINETICS shall pay
EMORY the amount indicated below, no later than thirty (30) days from the
occurrence of the indicated event:

          Event                                        Milestone

      * * *                                                * * *

      * * *                                                * * *

Once CYBERKINETICS has made a payment under this Article 3.3 upon the occurrence
of U.S. IDE Approval with respect to a particular Licensed Product,
CYBERKINETICS will not be obligated to make any payments under this Article 3.3
with respect to any other U.S. IDE Approval with respect to a Licensed Product
that is substantially similar to such Licensed Product or that represents only
an enhanced or improved version of such Licensed Product. CYBERKINETICS will be
obligated to make only one milestone payment under this Article 3.3 with respect
to each * * *, regardless of the number of Licensed Products that are sold * *
*.

      3.4.  Minimum Annual Royalties. Beginning on the * * * anniversary of the
Effective Date, on each anniversary of the Effective Date CYBERKINETICS shall
pay EMORY a minimum annual royalty of * * *. CYBERKINETICS may credit the
minimum annual royalty paid under this Article 3.4 against any royalties that
become payable to EMORY under Article 3.2 during the year to which such minimum
annual royalty relates.

      3.5.  Reimbursement for Patent Costs. CYBERKINETICS shall, within fifteen
(15) days of execution of this Agreement, pay EMORY the sum of * * * to
reimburse EMORY for costs incurred by EMORY as of the execution date of the
License Agreement in prosecuting and defending the Licensed Patents.

      3.6.  Equity. CYBERKINETICS shall issue to EMORY * * * shares of
CYBERKINETICS common stock. The Equity transaction between CYBERKINETICS and
EMORY shall be fully specified in a separate Stock Purchase Agreement made and
entered into as of the Effective Date of this Agreement.

                        ARTICLE 4. REPORTS AND ACCOUNTING

      4.1.  Royalty Reports and Records. During the term of this Agreement,
CYBERKINETICS shall furnish, or cause to be furnished to EMORY, written reports
relating to each of CYBERKINETICS, CYBERKINETICS 's Affiliates and Sublicensees
fiscal quarters showing:

                  (i)   the gross selling price of all Licensed Products Sold by
CYBERKINETICS, its Affiliates and Sublicensees, in each country of the Licensed
Territory

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       7
<PAGE>

during the reporting period, together with the calculations of Net Sales in
accordance with Article 1.13;

                  (ii)  the royalties payable in Dollars, which shall have
accrued hereunder with respect to such reporting period in respect to such Net
Sales;

                  (iii) the exchange rates, if any, used in determining the
royalties payable;

                  (iv)  a summary of all reports provided to CYBERKINETICS by
CYBERKINETICS' Sublicensees;

                  (v)   the occurrence of any event triggering a Milestone
Payment obligation in accordance with Article 3.3.

Reports shall be made semiannually until the first Sale of a Licensed Product
and quarterly thereafter. Semiannual reports shall be due within thirty (30)
days of the close of every second and fourth CYBERKINETICS fiscal quarter.
Quarterly reports shall be due within thirty (30) days of the close of every
CYBERKINETICS fiscal quarter. CYBERKINETICS shall keep accurate records in
sufficient detail to enable royalties and other payments payable hereunder to be
determined. CYBERKINETICS shall be responsible for all royalties and late
payments that are due to EMORY that have not been paid by CYBERKINETICS'
Affiliates and Sublicensees. CYBERKINETICS' Sublicensees shall have, and shall
be notified by CYBERKINETICS that they have, the option of making any royalty
payment directly to EMORY.

      4.2.  Right to Audit. EMORY shall have the right, upon prior notice to
CYBERKINETICS, not more than once in each CYBERKINETICS fiscal year, through an
independent public accountant selected by EMORY and acceptable to CYBERKINETICS,
which acceptance shall not be unreasonably refused, to have access during
CYBERKINETICS' normal business hours as may be reasonably necessary to verify
the accuracy of the royalty reports required to be furnished by CYBERKINETICS
pursuant to Article 5.1 of the Agreement. CYBERKINETICS shall include in any
sublicenses granted pursuant to this Agreement a provision requiring the
Sublicensee to keep and maintain records of Sales made pursuant to such
sublicense and to grant access to such records by EMORY's independent public
accountant. If such independent public accountant's report shows any
underpayment of royalties by CYBERKINETICS, its Affiliates or Sublicensees,
within thirty (30) days after CYBERKINETICS' receipt of such report,
CYBERKINETICS shall remit or shall cause its Sublicensees to remit to EMORY:

                  (i)   the amount of such underpayment; and

                  (ii)  if such underpayment exceeds * * * of the total
royalties owed for the fiscal year then being reviewed, the reasonably necessary
fees and expenses of such independent public accountant performing the audit.
Otherwise, EMORY's accountant's fees and expenses shall be borne by EMORY. Any
overpayment of royalties shall be fully creditable against future royalties
payable in any subsequent royalty periods.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       8
<PAGE>

      4.3.  Confidentiality of Records. All information subject to review under
this Article 4 shall be confidential. Except where otherwise provided by law,
EMORY and its accountant shall retain all such information in confidence.

                               ARTICLE 5. PAYMENTS

      5.1.  Payment Due Dates. Royalties, sublicense fees and other payments
payable to EMORY as a result of activities occurring during the period covered
by each royalty report provided for under Article 4 of this Agreement shall be
due and payable within fifteen (15) days of the date such royalty report is due.
Payments of royalties in whole or in part may be made in advance of such due
date. Any payment in excess of one hundred thousand dollars ($100,000.00) shall
be made by wire transfer to an account of EMORY designated by EMORY from time to
time; provided, however, that in the event that EMORY fails to designate such
account, CYBERKINETICS or its Affiliates and Sublicensees may remit payment to
EMORY at the address applicable for the receipt of notices hereunder; providing,
further, that any notice by EMORY of such account or change in such account,
shall not be effective until fifteen (15) days after receipt thereof by
CYBERKINETICS.

      5.2.  Currency Restrictions. Except as hereinafter provided in this
Article 5.2, all royalties shall be paid in Dollars. If, at any time, legal
restrictions prevent the prompt remittance of part of or all royalties with
respect to any country in the Licensed Territory where Licensed Products are
Sold, CYBERKINETICS, its Affiliates or Sublicensees shall have the right and
option to make such payments by depositing the amount thereof in local currency
to EMORY's account in a bank or depository in such country.

      5.3.  Interest. Royalties and other payments required to be paid by
CYBERKINETICS pursuant to this Agreement shall, if overdue, bear interest at the
lesser of (a) * * * or (b) * * * ten percent (10%)* * *. The payment of such
interest shall not foreclose EMORY from exercising any other rights it may have
because any payment is overdue.

                  ARTICLE 6. DEVELOPMENT AND MARKETING PROGRAM

      6.1.  Diligence Obligations. CYBERKINETICS shall directly, or in
collaboration with Affiliates, alliances and Sublicensees, use commercially
reasonable efforts to:

                  (i)   conduct research and development programs relating to
the use of Licensed Patents and Licensed Know-How;

                  (ii)  promptly register Licensed Products with regulatory
authorities in the Licensed Territory; and

                  (iii) market the Licensed Products in accordance with its
business plans and objectives.

      6.2.  Fulfillment; Conversion.

            (a)   For purposes of this Agreement, "commercially reasonable
efforts" shall mean the use of reasonable efforts including, to the extent
appropriate, pursuing sublicenses or corporate

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       9
<PAGE>

alliances, consistent with those used by comparable biotechnology companies in
the United States in research and development projects for medical devices or
kits deemed to have commercial value comparable to the Licensed Products.

            (b)   CYBERKINETICS' obligations set forth in this Article 6 shall
be deemed to have been fully satisfied during the following time periods if
CYBERKINETICS accomplishes the following specified milestones:

                  (i)   Prior to * * * . CYBERKINETICS causes * * * with respect
to * * * to occur prior to * * * ;

                  (ii)  Prior to * * * . CYBERNETICS causes the * * * with
respect to a * * * to occur by * * *; and

                  (iii) After * * * . CYBERNETICS * * * within * * * following
the * * * for a Licensed Product.

            (c)   For clarity, the diligence obligations set forth in this
Article 6 are independent of the minimum annual royalties payable pursuant to
Article 3.4 and the payment of such minimum annual royalties will not relieve
CYBERKINETICS of its obligations under this Article 6.

            (d)   CYBERKINETICS shall provide regular reports to EMORY after
submission of its U.S. 510 (k) filing(s) for Licensed Products concerning the
status of such filing(s) until final approval thereof, including any final
decision not to comply with any FDA request.

            (e)   CYBERKINETICS will notify EMORY promptly after any final
decision by CYBERKINETICS to permanently abandon development of Licensed
Products based upon any portion of the Licensed Technology.

            (f)   In the event CYBERKINETICS fails to meet any diligence
requirement set forth herein, EMORY shall have the option in its sole discretion
to (i) terminate the Agreement within the entire Licensed Territory or any
portion of the Licensed Territory for such application or indication, (ii)
convert the license granted in this License Agreement into a nonexclusive
license within the entire Licensed Territory or any portion of the Licensed
Territory for such indication, or (iii) terminate the Agreement within a portion
of the Licensed Territory and convert the license granted in this Agreement into
a non-exclusive license within a portion of the Licensed Territory. In order to
allow EMORY to determine to exercise any of the foregoing rights, in the event
CYBERKINETICS fails to meet any diligence requirement set forth herein,
CYBERKINETICS shall, on EMORY'S request, subject to agreement between
CYBERKINETICS and EMORY of terms and conditions of confidentiality, permit EMORY
to have access to all CYBERKINETICS' data related to CYBERKINETICS' development
efforts with respect to the Licensed Technology for the purpose of allowing
EMORY to assess the commercial potential of the Licensed Technology.

            (g)   Prior to exercising any rights under this Article, EMORY shall
give CYBERKINETICS sixty (60) days' prior written notice and shall meet with
CYBERKINETICS, at CYBERKINETICS' request and expense, during such sixty (60) day
period, to discuss any disagreements about whether CYBERKINETICS has complied
with the requirements of this

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       10
<PAGE>

Article. CYBERKINETICS shall (i) within sixty (60) days of CYBERKINETICS'
receipt of written notice of such failure, provide to EMORY a commercially
reasonable plan to remedy such failure and (ii) cure such failure in accordance
with such plan within the time provided for under such plan. If CYBERKINETICS
fails to provide such a commercially reasonable plan within sixty (60) days or
does not cure such failure in accordance with such plan within the time provided
for under such plan, EMORY shall have the right in its sole discretion to
proceed with the exercise of all rights arid remedies provided for herein.

      6.3.  Progress Reports. CYBERKINETICS shall, no less frequently than once
every six (6) months until CYBERKINETICS has achieved Regulatory Approval for a
Licensed Product, provide EMORY with a written report detailing all activities
of CYBERKINETICS, its Affiliates and Sublicensees related to developing Licensed
Products and pursuing Regulatory Approval of Licensed Products to the extent
reasonably necessary for EMORY to review CYBERKINETICS' progress under Article
6.2. Such reports shall further, no less frequently than once per year,
incorporate sufficient and quantified detail on the resources allocated by
CYBERKINETICS to enable EMORY to determine that CYBERKINETICS is diligently
pursuing its research and development in accordance with its business plans and
this Agreement.

      6.4.  Development Outside United States. As soon as practicable and in
accordance with CYBERKINETICS' corporate goals and its obligations under this
Agreement, CYBERKINETICS shall directly, or in collaboration with Affiliates and
Sublicensees, commence its commercially reasonable efforts:

                  (i)   to obtain Regulatory Approval for a Licensed Product in
such other countries of the Licensed Territory as CYBERKINETICS or
CYBERKINETICS' Affiliates and Sublicensees deem appropriate; and

                  (ii)  upon Regulatory Approval of a Licensed Product in a
particular country diligently commence efforts to market such Licensed Product
in such country.

                         ARTICLE 7. PATENT PROSECUTION

      7.1.  CYBERKINETICS shall be responsible for preparing, filing,
prosecuting, maintaining and defending all Licensed Patents. CYBERKINETICS shall
provide EMORY with copies of all filings and relevant documentation and a
reasonable opportunity in advance to comment on such filings. CYBERKINETICS will
not abandon any patent application in the Licensed Patents, or make
prosecution-related decisions that would have a material impact on the nature or
scope of any claims in such patent applications, without giving EMORY a
reasonable opportunity to comment on such action or decision.

      7.2.  CYBERKINETICS shall bear all costs in connection with the
preparation, filing, prosecution, maintenance and defense of the Licensed
Patents.

      7.3.  In the event that CYBERKINETICS determines to abandon prosecution
of, or to cease to maintain, any Licensed Patent in any country, CYBERKINETICS
shall so notify EMORY and shall permit EMORY, in its sole discretion, at EMORY's
expense, to continue to prosecute or

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       11
<PAGE>

maintain such Licensed Patent in such jurisdiction, and CYBERKINETICS shall
cooperate with EMORY in regard thereto. If EMORY does so prosecute, the licenses
granted to CYBERKINETICS under Article 2.1 shall terminate in such country with
respect to any Licensed Patents issuing in such country as a result of such
prosecution.

      7.4.  Each party shall, and shall cause its Affiliates, employees,
attorneys and agents to, cooperate fully with the other party and provide all
information and data and execute any documents reasonably required or requested
in order to allow the other party to prepare, prosecute, file, and maintain
patents and patent applications pursuant to this Article 7 for no additional
compensation.

                             ARTICLE 8. INFRINGEMENT

      8.1.  Third Party Infringement. CYBERKINETICS and EMORY shall each
promptly notify the other in writing of any alleged or threatened infringement
or claim of invalidity (hereinafter "Infringement") of which they become aware
of patents included in the Licensed Patents, and the parties shall consult
concerning the action to be taken. CYBERKINETICS shall have the right, but not
the obligation, to prosecute or defend at its own expense any such Infringement.
In such event, CYBERKINETICS shall have the right, if EMORY is a legally
indispensable party, to bring such suit or action in the name of EMORY.
CYBERKINETICS shall pay, on behalf of and instead of EMORY, any order for costs
that may be made against EMORY by reason of it being joined as a party plaintiff
in such proceedings by CYBERKINETICS, provided that EMORY will not be obligated
to reimburse CYBERKINETICS for any costs so paid by CYBERKINETICS. CYBERKINETICS
shall have sole control of any such suit or action and all negotiations for its
settlement or compromise; provided, however, that CYBERKINETICS shall not settle
or compromise any such suit or action or enter into any consent order for the
settlement or compromise thereof that adversely affects any rights of EMORY
hereunder without the prior written consent of EMORY, not to be unreasonably
withheld.

      If, within sixty (60) days after CYBERKINETICS first becomes aware of any
Infringement of the Licensed Patents, CYBERKINETICS fails to cause such
Infringement to terminate or to bring a suit or action to compel termination,
EMORY shall have the right, but not the obligation, to bring such suit or action
to compel termination at the sole expense of EMORY. In such event, EMORY shall
have the right, if CYBERKINETICS is a legally indispensable party, to bring such
suit or action in the name of CYBERKINETICS. EMORY shall hold pay, on behalf of
and instead of CYBERKINETICS, any order for costs that may be made against
CYBERKINETICS by reason of it being joined as a party plaintiff in such
proceedings by EMORY, provided that CYBERKINETICS will not be obligated to
reimburse EMORY for any costs so paid by EMORY. EMORY shall have sole control of
any such suit or action and all negotiations for its settlement or compromise;
provided, however, that EMORY shall not settle or compromise any such suit or
action or enter into any consent order for the settlement or compromise thereof
that adversely affects any rights of CYBERKINETICS hereunder without the prior
written consent of CYBERKINETICS, not to be unreasonably withheld.

      8.2.  Allocation of Recovery. Any recovery or damages derived from an
action under this Article 8 shall be used (i) first to reimburse the initiating
party for all legal expenses incurred

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       12
<PAGE>

by it relating to the suit and (ii) second to reimburse the non-initiating party
for all legal expenses incurred by it relating to the suit, with any remaining
recovery allocated between the parties as follows:

            (a)   To the extent the remaining amount is attributed to sales of
such infringing products, CYBERKINETICS shall receive an amount equal to such
amount less the royalties that would have been payable on such sales pursuant to
this Agreement had such sales been made by CYBERKINETICS, which royalty amount
shall be paid to EMORY.

            (b)   To the extent the remaining amount is attributed to lost
royalties owed to EMORY under subparagraph (a) as a result of the infringement,
EMORY shall receive an amount equal to the royalties payable to EMORY under this
Agreement multiplied by any multiple of damages awarded in such action.

            (c)   Any remaining recovery amount not attributed to sales of such
infringing products shall be divided with sixty-seven percent (67%) of such
remaining amount allocated to the party initiating such proceedings and
thirty-three percent (33%) of such remaining amount allocated to the
non-initiating party.

      8.3.  Offset by CYBERKINETICS. CYBERKINETICS shall not offset its
out-of-pocket expenses incurred in regard to any such legal proceedings which
CYBERKINETICS initiates or carries on against any royalty payments or other
payments owed to EMORY except in the case of an action initiated independently
by a third party to invalidate any claims of the Licensed Patents, such as
through a reexamination. If such action occurs, CYBERKINETICS may suspend
royalty payments payable to EMORY until the action is concluded, at which time
CYBERKINETICS will make such suspended royalty payments to EMORY based upon the
Valid Claims then existing with respect to the Licensed Patents.

      8.4.  EMORY's Right to Pursue Third Party Infringers If CYBERKINETICS
shall fail, within sixty (60) days after receiving notice from EMORY of a
potential infringement, or providing EMORY with notice of such infringement, to
either (a) terminate such infringement or (b) institute an action to prevent
continuation thereof and, thereafter to prosecute such action diligently, or if
CYBERKINETICS notifies EMORY that it does not plan to terminate the infringement
or institute such action, then EMORY shall have the right to do so at its own
expense. CYBERKINETICS shall cooperate with EMORY in such effort including being
joined as a party to such action if necessary. EMORY shall be entitled to retain
all damages or costs awarded to EMORY in such action.

             ARTICLE 9. EXCLUSION OF WARRANTIES AND INDEMNIFICATION

      9.1.  Warranties of EMORY.

            (a)   EMORY represents and warrants that, to the best of its
knowledge:

                  (i)   EMORY has disclosed to CYBERKINETICS all potential
patent rights in the control of third parties known to EMORY which may be needed
to commercialize the

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       13
<PAGE>

Licensed Patents, provided that for purposes of this representation and
warranty, "EMORY" shall mean the Inventor and any employees of EMORY who work in
the technology transfer area, and CYBERKINETICS acknowledges that EMORY has not
undertaken any investigation with respect to the potential patent rights of any
third party; and

                  (ii)  Appendix A is a complete list of all patents and patent
applications included in the Licensed Patents as of the date hereof. EMORY will
from time to time during the term of this Agreement, promptly provide
CYBERKINETICS with, upon request, with an updated version of Appendix A.

                  (iii) EMORY is not aware of any patent infringement or notice
of any pending claim of infringement in respect of the Licensed Patents.

            (b)   EMORY further represents and warrants that it is the exclusive
owner of all rights, title and interests in the patents and patent applications
identified in Appendix A as of the date hereof, subject to the rights of the
U.S. Government.

      9.2.  Warranties of Each Party. Each party hereto represents to the other
that it is free to enter into this Agreement and to carry out all of the
provisions hereof, including, in the case of EMORY, its grant to CYBERKINETICS
of the license described in Article 2.1.

      9.3.  Merchantability and Exclusion of Warranties. CYBERKINETICS possesses
the necessary expertise and skill in the technical areas pertaining to the
Licensed Patents, Licensed Products and Licensed Know-How to make, and has made,
its own evaluation of the capabilities, safety, utility and commercial
application of the Licensed Patents, Licensed Products and Licensed Know-How.
ACCORDINGLY, EXCEPT AS SET FORTH IN ARTICLE 9.1 AND 9.2, EMORY DOES NOT MAKE ANY
REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE LICENSED PATENTS,
LICENSED KNOW-HOW OR LICENSED PRODUCTS AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY OTHER IMPLIED
WARRANTIES WITH RESPECT TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL
APPLICATION OF THE LICENSED PATENTS, LICENSED KNOW-HOW OR LICENSED PRODUCTS.

      9.4.  Indemnification by CYBERKINETICS. CYBERKINETICS shall defend,
indemnify, and hold harmless the EMORY Indemnitees, from and against any and all
claims, demands, losses, liabilities, expense, or damage (including
investigative costs, court costs and reasonable attorneys' fees) the EMORY
Indemnitees may suffer, pay, or incur as a result of claims, demands or actions
against any of the EMORY Indemnitees arising or alleged to arise by reason of,
or in connection with, any and all personal injury (including death) and
property damage caused or contributed to, in whole or in part, by CYBERKINETICS'
or CYBERKINETICS' Affiliates, contractors, agents, or Sublicensees' manufacture,
testing, design, use, Sale, or labeling of any Licensed Products. CYBERKINETICS'
obligations under this Article shall survive the expiration or termination of
this Agreement for any reason.

      9.5.  Insurance. Without limiting CYBERKINETICS' indemnity obligations
under

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       14
<PAGE>

Article 9.4, CYBERKINETICS shall, prior to any clinical trial or Sale of any
Licensed Product, cause to be in force, an "occurrence based type" or "claims
made type" (with reasonable tail coverage) liability insurance policy which:

            (a)   insures Indemnitees for all claims, damages, and actions
mentioned in Article 9 of this Agreement; and

            (b)   includes a contractual endorsement providing coverage for all
liability which may be incurred by Indemnitees in connection with this
Agreement; and

            (c)   requires the insurance carrier to provide EMORY with no less
than thirty (30) days' written notice of any change in the terms or coverage of
the policy or its cancellation; and

            (d)   provides Indemnitees a comprehensive general/product liability
coverage in an amount no less than * * * per occurrence for bodily injury and *
* * per occurrence for property damage, subject to a reasonable aggregate
amount; and

            (e)   in the event that CYBERKINETICS, its Affiliates or
Sublicensees decide to go to market with a Licensed Product it shall, to the
extent available at commercially reasonable rates arrange (prior to the Sale of
any Licensed Product) and shall continue for the term of this Agreement and for
a period of * * * years thereafter an insurance policy or policies of product
liability which provide Licensee, its affiliates or Sublicensees with coverage
for injury or damage arising to users of Licensed Products in an amount no less
than * * * per claim, subject to annual aggregate of * * *; and

            (f)   CYBERKINETICS shall provide EMORY with a copy of any such
insurance policy prior to the commencement of clinical trials or the first Sale
of any Licensed Product and on each renewal and/or replacement of the policy
together with a copy of any schedule and evidence of payment of the premium.
Company will also advise EMORY with written notice within 30 days of any
material change in the terms or coverage of the policy or its cancellation.

            (g)   EMORY may periodically review the adequacy of the minimum
limits of liability insurance specified in this Article 9.5. EMORY reserves the
right to require CYBERKINETICS to adjust the liability insurance coverage above
within reason and without significantly increasing CYBERKINETICS' annual
insurance premiums.

      9.6.  Occurrence Based Coverage Not Available. If CYBERKINETICS is unable
to obtain "occurrence based type" liability insurance, CYBERKINETICS shall
procure "claims made type" liability coverage to be effective prior to any
clinical trial or Sale of any Licensed Products, and throughout the term of this
Agreement and "tail coverage", extending at least ten (10) years after
termination of this Agreement. CYBERKINETICS shall notify EMORY prior to its
first clinical trial or commercial Sale of any Licensed Product, of all
insurance coverage and other assets available to CYBERKINETICS to meet
CYBERKINETICS' obligations under Article 9 of this Agreement.

      9.7.  Notice of Claims: Indemnification Procedures.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       15
<PAGE>

            (a)   CYBERKINETICS shall promptly notify EMORY of any claims
involving any Indemnitees for which indemnification is or may be provided in
Article 9.4 and shall advise EMORY of the policy amounts that might be needed to
defend and pay any such claims.

            (b)   An Indemnitee, which intends to claim indemnification under
this Article shall promptly notify the other party (the "Indemnitor") in writing
of any matter in respect of which the Indemnitee or any of its employees or
agents intend to claim such indemnification. The Indemnitee shall permit, and
shall cause its employees and agents to permit, the Indemnitor, at its
discretion, to settle any such matter and agrees to the complete control of such
defense or settlement by the Indemnitor; provided, however, that such settlement
does not adversely affect the Indemnitee's rights hereunder or impose any
obligations on the Indemnitee in addition to those set forth herein in order for
it to exercise such rights and that the Indemnitee makes no statement or
undertakes any action that may prejudice the ability of the Indemnitor to settle
any such claim. No such matter shall be settled without the prior written
consent of the Indemnitor and the Indemnitor shall not be responsible for any
legal fees or other costs incurred other than as provided herein. The
Indemnitee, its employees and agents shall cooperate fully with the Indemnitor
and its legal representatives in the investigation and defense of any matter
covered by the applicable indemnification. The Indemnitee shall have the right,
but not the obligation, to be represented by counsel of its own selection and at
its expense.

                           ARTICLE 10. CONFIDENTIALITY

      10.1. Treatment of Confidential Information. Except as otherwise provided
hereunder, during the term of this Agreement and for a period of * * *
thereafter:

                  (i)   CYBERKINETICS and its Affiliates and Sublicensees shall
retain in confidence and use only for purposes of this Agreement, any written
information and data supplied by EMORY to CYBERKINETICS under this Agreement and
marked as proprietary;

                  (ii)  EMORY shall retain in confidence and use only for
purposes of this Agreement any written information and data supplied by
CYBERKINETICS or on behalf of CYBERKINETICS to EMORY under this Agreement and
marked as proprietary.

           For purposes of this Agreement, all such information and data which,
a party is obligated to retain in confidence shall be called "Information".

      10.2  Right to Disclose. To the extent that it is reasonably necessary to
fulfill its obligations or exercise its rights under this Agreement, or any
rights which survive termination or expiration hereof, each party may disclose
the other Party's Information to its Affiliates, Sublicensees, consultants,
outside contractors, governmental regulatory authorities and clinical.
investigators and in the case of CYBERKINETICS, its collaborators and potential
investors, on the condition that such entities or persons agree:

                  (i)   to keep such Information confidential for at least the
same time periods and to the same extent as the disclaiming party is required to
keep the Information

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       16
<PAGE>

confidential;

                  (ii)  to use such Information only for such purposes as the
disclosing party is authorized to use the Information under this Agreement;

                  (iii) not to use EMORY's name for any commercial purpose
without the prior written consent of EMORY.

      Each party, its Affiliates and Sublicensees may disclose the other party's
Information to the government or other regulatory authorities to the extent that
such disclosure is necessary for the prosecution and enforcement of patents
included within the Licensed Patents, or authorizations to conduct clinical
trials or commercially market Licensed Products, provided that such party is
entitled to engage in such activities under this Agreement or is legally
required to make such disclosures.

      10.3. Release from Restrictions. The obligation not to disclose the other
party's Information shall not apply to any part of such Information that:

                  (i)   is or becomes disclosed in a patent or patent
application, published or otherwise part of the public domain, other than by
unauthorized acts of the receiving party or its Affiliates or Sublicensees in
contravention of this Agreement;

                  (ii)  is disclosed to the receiving party or its Affiliates or
Sublicensees by a third party provided that such third party was not obligated
to the other party to keep such information confidential; or

                  (iii) prior to disclosure under this Agreement, was already in
the possession of the receiving party, its Affiliates or Sublicensees, provided
that such Information was not obtained directly or indirectly from the other
party under this Agreement with an obligation to keep such information
confidential;

                  (iv)  the receiving party is able to demonstrate results from
research and development by the receiving party or its Affiliates or
Sublicensees independent of disclosures from the other party, provided that the
persons developing such information have not had exposure to the Information
received from the disclosing party;

                  (v)   is required by law to be disclosed by the receiving
party, provided that the receiving party shall notify the other party
immediately upon learning of such requirement in order to give the other party
reasonable opportunity to oppose such requirement; or

                  (vi)  the disclosing party agrees in writing may be disclosed.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       17
<PAGE>

                        ARTICLE 11. TERM AND TERMINATION

      11.1. Term. Unless sooner terminated as otherwise provided in this
Agreement, the term of this Agreement shall commence on the Effective Date and
shall continue in full force and effect, until * * *.

      11.2. Termination. EMORY shall have the right to terminate this Agreement
upon the occurrence of any one or more of the following events and provided that
EMORY has given CYBERKINETICS the notice required in Article 11.3 and
CYBERKINETICS has failed to cure the breach described in such notice:

            (a)   failure of CYBERKINETICS to make any payment required pursuant
to this Agreement when due;

            (b)   failure of CYBERKINETICS to render reports to EMORY as
required by this Agreement;

            (c)   the institution of any proceeding by CYBERKINETICS under any
bankruptcy, insolvency, or moratorium law;

            (d)   any assignment by CYBERKINETICS of substantially all of its
assets for the benefit of its creditors;

            (e)   placement of CYBERKINETICS' assets in the hands of a trustee
or a receiver unless the receivership or trust is dissolved within thirty (30)
days thereafter and provided that in the case of in involuntary bankruptcy
proceeding, which is contested by CYBERKINETICS, such termination shall not
become effective until the bankruptcy court of jurisdiction has entered an order
upholding the petition;

            (f)   a formal decision reduced to writing and delivered to EMORY by
CYBERKINETICS or CYBERKINETICS' assignee of all of CYBERKINETICS' rights under
this Agreement to quit the business of commercializing the Licensed Patents and
Licensed Know-How or developing or selling Licensed Products; or

            (g)   the breach by CYBERKINETICS of any other material term of this
Agreement.

      11.3. Exercise. Subject to Article 15.11, EMORY may exercise its right of
termination by giving CYBERKINETICS, its trustees, receivers or assigns, thirty
(30) days' (or such other extended period agreed in writing by the parties)
prior written notice of EMORY's election to terminate. Such notice shall include
the basis for such termination. Upon the expiration of such period, this
Agreement shall automatically terminate unless CYBERKINETICS has cured the
breach where such breach is capable of being remedied within such period or
extended period as applicable. Such notice and termination shall not prejudice
EMORY's right to receive royalties up to the point of termination or other sums
due to EMORY hereunder and shall not prejudice any cause of action or claim of
EMORY accrued or to accrue on account of any breach or default by

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       18
<PAGE>

CYBERKINETICS.

      11.4. Failure to Enforce. The failure of EMORY, at any time, or for any
period of time, to enforce any of the provisions of this Agreement, shall not be
construed as a waiver of such provisions or as a waiver of the right of EMORY
thereafter to enforce each and every such provision of this Agreement.

      11.5. Termination by CYBERKINETICS. CYBERKINETICS shall have the right to
terminate this Agreement upon the occurrence of either of the following events:

            (a)   the breach of a material term of this Agreement by EMORY;

            (b)   if the Sale of Licensed Products requires approval by any
government agency, and after diligent pursuit of such approval, including but
not limited to: performing all reasonable tests or analyses as prescribed by
such agency regulations; submitting all relevant data to such agency; and
pursuing reasonable available administrative procedures and appeal processes
permitted by such agency and applicable law, CYBERKINETICS reasonably determines
it is unable to obtain approval for the Sale of Licensed Products or reasonably
determines such approval would, in CYBERKINETICS' sole judgment, be too
restrictive to justify continued development of a Licensed Product,
CYBERKINETICS may notify EMORY in writing of the final denial of approval to
Sell Licensed Products and CYBERKINETICS' desire to terminate this Agreement or
parts hereof related to specific Licensed Technology from which such Licensed
Products that are denied Regulatory Approval have been developed; or

            (c)   upon CYBERKINETICS' convenience, upon ninety (90) days'
written notice to EMORY, provided that no such termination shall relieve
CYBERKINETICS of its obligation under Articles 3.1, 3.2, 3.3, 3.4, 3.5 and 3.6.
with respect to any milestone achieved and other payments made prior to the
effective date of such termination.

      11.6. Exercise. CYBERKINETICS may exercise its right of termination
pursuant to Article 11.5(a), by giving EMORY thirty (30) days' prior written
notice of CYBERKINETICS' election to terminate. The notice shall include the
basis for such termination. Upon the expiration of such period, this Agreement
shall automatically terminate unless EMORY has cured the breach. Such notice of
termination shall not prejudice any cause of action or claim of CYBERKINETICS
accrued or to accrue on account of any breach or default by EMORY.

      CYBERKINETICS may exercise its right of termination pursuant to Article
11.5 (b) as a result of the failure to obtain governmental approval to sell
Licensed Products by providing EMORY with a formal written request for such
termination enclosing evidence of the final denial of governmental approval.

      CYBERKINETICS may exercise its right of termination pursuant to Article
11.5 (c) by providing EMORY with written notice of such termination.

      11.7. Effect. In the event this Agreement is terminated because of
CYBERKINETICS' default, CYBERKINETICS shall return, or at EMORY's direction
destroy, all data, writings and other documents and tangible materials,
containing EMORY's Information and supplied to

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       19
<PAGE>

CYBERKINETICS by EMORY.

      Where the default for which this Agreement is terminated is set forth
under Articles 11.2(c) through (f) inclusive, subject to agreement between
CYBERKINETICS and EMORY of terms and conditions of confidentiality,
CYBERKINETICS shall provide EMORY access to CYBERKINETICS' product files
pertaining to the Licensed Products and design dossiers as well as data
generated by CYBERKINETICS' contractors and agents in the course of
CYBERKINETICS' efforts to develop Licensed Products or obtain governmental
approval for the Sale of Licensed Products to permit EMORY to assess the
commercial potential of the Licensed Technology. CYBERKINETICS agrees to
negotiate in good faith with EMORY and/or any potential licensee of the Licensed
Technology with respect to a license or sale of information, data and research
results then owned or controlled by CYBERKINETICS, including, but not limited
to, toxicity, efficacy and market research, to the extent such information, data
and research results are pertinent to the Licensed Technology. In such event,
CYBERKINETICS shall also grant EMORY and any replacement licensee of the
Licensed Technology the right to cross reference any regulatory filings (e.g.
510 (k), Registrations) made by CYBERKINETICS or its Affiliates with the FDA or
any corresponding foreign regulatory agency, in exchange for which EMORY or such
replacement licensee will reimburse CYBERKINETICS, on terms and at a rate to be
negotiated in advance in good faith by the parties involved, based on all
reasonable and documented direct and indirect, out-of-pocket costs incurred by
CYBERKINETICS in pursuing such regulatory approvals. CYBERKINETICS shall
cooperate (but shall not be required to incur any expense) with any such third
parties in pursuing governmental approval to sell any product covered by any
patent application or issued patent (which was formerly a Licensed Patent
licensed b1 EMORY to such third party.

                             ARTICLE 12. ASSIGNMENT

      CYBERKINETICS may grant, transfer, convey, or otherwise assign any or all
of its rights and obligations under this Agreement in conjunction with the
transfer of all, or substantially all, of the business interests of
CYBERKINETICS to which this Agreement relates including for the purposes of
corporate re-organization. EMORY's written consent, which shall not be
unreasonably withheld, shall be required prior to any other assignment of
CYBERKINETICS' rights or obligations under this Agreement.

                             ARTICLE 13. BANKRUPTCY

      In the event that CYBERKINETICS, for any reasons, plans the institution of
any proceeding under any bankruptcy, insolvency, or moratorium law of any
countries, CYBERKINETICS shall notify EMORY of its plan at least One Hundred and
Twenty (120) days prior to the official filing of such bankruptcy, insolvency,
or moratorium with government or legal authorities. In the event that this
Agreement or CYBERKINETICS' license to the Licensed Technology is transferred,
sold, novated or otherwise provided to a third party (the "Transferee") as part
of a bankruptcy or insolvency settlement under the ruling of a court of
competent jurisdiction, the obligations to pay royalties and other payments to
EMORY shall be borne by such Transferee.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       20
<PAGE>

                              ARTICLE 14. PUBLICITY

      Neither party shall use the name of the other, nor of any employee of such
party, in any publicity, marketing efforts, news release or any other commercial
activities without the prior written approval of an authorized representative of
the other party. Notwithstanding the foregoing, either party may disclose the
terms of this Agreement and the parties' relationship as required by law.

                            ARTICLE 15. MISCELLANEOUS

      15.1. Arbitration. Any disputes under this Agreement, shall be resolved
through arbitration conducted under the auspices of the American Arbitration
Association pursuant to that organization's rules for commercial arbitration and
shall have the right to enforce any such arbitral award. Any hearings shall be
held in Atlanta, Georgia. Both parties agree to be bound by any arbitral award
without prejudice to any other rights at law.

      15.2. Export Controls. CYBERKINETICS acknowledges that EMORY is subject to
United States laws and regulations controlling the export of technical data,
biological materials, chemical compositions and other commodities and that
EMORY's obligations under this Agreement are contingent upon compliance with
applicable United States export laws and regulations. The transfer of technical
data, biological materials, chemical compositions and commodities may require a
license from the cognizant agency of the United States government or written
assurances by CYBERKINETICS that CYBERKINETICS shall not export data or
commodities to certain foreign countries without the prior approval of certain
United States agencies. EMORY neither represents that an export license shall
not be required nor that, if required, such export license shall be issued.

      15.3. Legal Compliance. CYBERKINETICS shall use reasonable commercial
efforts to comply with all laws and regulations relating to its manufacture,
use, Sale, labeling or distribution of Licensed Products and shall not knowingly
take any action that would cause EMORY or CYBERKINETICS to violate any laws or
regulations.

      15.4. Independent Contractor. CYBERKINETICS' relationship to EMORY shall
be that of a licensee only. CYBERKINETICS shall not be the agent of EMORY and
shall have no authority to act for, or on behalf of, EMORY in any matter.
Persons retained by CYBERKINETICS as employees or agents shall not, by reason
thereof, be deemed to be employees or agents of EMORY.

      15.5. Patent Marking. CYBERKINETICS shall mark Licensed Products Sold in
the United States with United States patent numbers in accordance with
applicable U.S. laws as in effect from time to time. Products manufactured or
Sold in other countries shall be marked in compliance with the intellectual
property laws in force in such foreign countries.

      15.6. Place of Execution. This Agreement and any subsequent modifications
or amendments hereto shall be deemed to have been executed in the State of
Georgia. This

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       21
<PAGE>

Agreement shall not become effective or binding upon EMORY until signed by its
Assistant Vice President and Director of the Office of Technology Transfer in
the State of Georgia.

      15.7. Governing Law. This Agreement and all amendments, modifications,
alterations, or supplements hereto, and the rights of the parties hereunder,
shall be construed under and governed by the laws of the State of Georgia and
the United States of America. Unless otherwise resolved under the provisions of
Article 15.1, only courts in the State of Georgia shall have jurisdiction to
hear and decide any controversy or claim between the parties arising under or
relating to this Agreement.

      15.8. Entire Agreement. This Agreement constitutes the entire agreement
between EMORY and CYBERKINETICS with respect to the subject matter hereof and
shall not be modified, amended or terminated, except as herein provided or
except by another agreement in writing executed by the parties hereto.

      15.9. Survival. Articles 9, 10, 11, 14, and 15 shall survive termination
of this Agreement for any reason. Article 11.7 shall survive termination
pursuant to Article 11.2.

      15.10. Severability. All rights and restrictions contained herein maybe
exercised and shall be applicable and binding only to the extent that they do
not violate any applicable laws and are intended to be limited to the extent
necessary so that they will not render this Agreement illegal, invalid or
unenforceable. If any provision or portion of any provision of this Agreement,
not essential to the commercial purpose of this Agreement, shall be held to be
illegal, invalid or unenforceable by a court of competent jurisdiction, it is
the intention of the parties that the remaining provisions or portions thereof
shall constitute their agreement with respect to the subject matter hereof, and
all such remaining provisions, or portions thereof, shall remain in full force
and effect. To the extent legally permissible, any illegal, invalid or
unenforceable provision of this Agreement shall be replaced by a valid
provision, which shall implement the commercial purpose of the illegal, invalid,
or unenforceable provision. In the event that any provision essential to the
commercial purpose of this Agreement is held to be illegal, invalid or
unenforceable and cannot be replaced by a valid provision which will implement
the commercial purpose of this Agreement, this Agreement and the rights granted
herein shall terminate provided, however, that it is replaced forthwith by a
legally enforceable substitute agreement that maintains the contractual
relationship between the parties as contemplated herein including specifically,
the rights and privileges granted to CYBERKINETICS in respect of the Licensed
Technology.

      15.11. Force Majeure. Any delays in, or failure of performance of any
party to this Agreement, shall not constitute a default hereunder, or give rise
to any claim for damages, if and to the extent caused by occurrences beyond the
control of the party affected, including, but not limited to, acts of God,
strikes or other concerted acts of workmen, civil disturbances, fires, floods,
explosions, riots, war, rebellion, sabotage, acts of governmental authority or
failure of governmental authority to issue licenses or approvals which may be
required.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       22
<PAGE>

                               ARTICLE 16. NOTICES

      All notices, statements, and reports required to be given by one party to
the other shall be in writing and shall be deemed to have been given (i) upon
electronic confirmation of delivery, if sent by facsimile to the recipient below
followed by a copy which shall be sent by overnight delivery to the same
recipient, or (ii) upon delivery in person, or (iii) upon the expiration of five
(5) days after deposit in a lawful mail depository in the country of residence
of the party giving the notice, registered or certified postage prepaid, and
addressed as follows:

To EMORY:                   Director, Office of Technology Transfer
                            Emory University
                            2009 Ridgewood Drive
                            Atlanta, Georgia 30322

Notices related to EMORY's equity position in CYBERKINETICS, which include, but
are not limited to, stock, stock options, voting rights, etc. should be sent to:

                            Emory University
                            Office of Vice President for Finance & Treasurer
                            312 Administration Building
                            Atlanta, GA 30322

To CYBERKINETICS :          President
                            Cyberkinetics, Inc.
                            109 Hazard Avenue
                            Providence, RI 02906

With a copy to:             Ropes & Gray
                            One International Place
                            Boston, MA 02110
                            Attn: Geoffrey B. Davis, Esq.

Either party hereto may change the address to which notices to such party are to
be sent by giving notice to the other party at the address and in the manner
provided above. Any notice may be given, in addition to the manner set forth
above, by courier, facsimile or email, provided that the party giving such
notice obtains acknowledgement by courier, facsimile or email that such notice
has been received by the party to be notified. Notice made in this manner shall
be deemed to have been given when such acknowledgement has been transmitted.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       23
<PAGE>

      IN WITNESS WHEREOF, EMORY and CYBERKINETICS have caused this Agreement to
be signed by their duly authorized representatives, as of the Effective Date.

EMORY UNIVERSITY:                             CYBERKINETICS, INC.:

By:___________________________                By:______________________________

Name: Mary L. Severson, Ph.D., J.D.           Name:____________________________

Title: Assistant Vice President & Director,   Title:___________________________
       Office of Technology Transfer

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       24
<PAGE>

                                   Appendix A
                                Licensed Patents

U.S. Patent No. * * * for "* * *" Issued * * *.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission

                                       25<PAGE>

                                                                    EXHIBIT 10.7

                                    EXHIBIT 1
                            100 Foxborough Boulevard
                         Foxborough, Massachusetts 02035
                                (The "Building")

                                BASIC PROVISIONS
                            AND LEASE REFERENCE DATA

Execution Date:           May 9th, 2003

Tenant                    Cyberkinetics, Inc.
And                       100 Foxborough Boulevard
Original Address:         Suite 240
                          Foxborough, MA 02035

Landlord                  Charles E. Harlfinger, Trustee of 100 & 200
And                       Foxborough Boulevard Realty Trust under Declaration
Original Address:         of Trust dated September 10, 1992 and filed with
                          the Norfolk County Registry District of the Land
                          Court on September 28, 1992 as Document No.636296;
                          c/o Foxborough Boulevard Management, Inc., 117
                          Eastman Street, South Easton, MA. 02375.

Building:                 The building in the Town of Foxborough, Norfolk
                          County, Massachusetts known as and numbered 100
                          Foxborough Boulevard.

Property:                 The Building and the land parcel on which it is
                          located (including adjacent sidewalks.)

Commencement Date:        The later of (a) June 1, 2003 or (b) the date
                          Landlord's Work is substantially complete pursuant
                          to Section 6 of this Lease and Landlord delivers
                          the Premises to Tenant

Term:                     The Commencement date through May 31, 2007.

Premises Description      Approximately 6,169 square feet of Rentable Area
                          located on the second floor of the Building and
                          designated as Suite 240.

Building Rentable Area:   Approximately 65,000 square feet.

<PAGE>

Basic Rent:               June 1, 2003 - July 31, 2003: Free Rent
                          August 1, 2003 - May 31, 2004: $17.65 per square foot
                          per annum pro rated over 10 months ($9,075.00 per
                          month)
                          June 1, 2004 - May 31, 2005: $ 19.00 per square foot
                          per annum ($ 9,767.58 per month)
                          June 1, 2005 - May 31, 2007: $20.00 per square foot
                          per annum ($10,281.67 per month)

Electric:                 Tenant will pay an additional $1.25 P.S.F. for its
                          use of electricity. ($ 642.60 per month)

Preparation of the        In a mutually acceptable location, Landlord shall
Premises:                 construct a conference room for Tenant's use.
                          Landlord shall clean Premises prior to commencement
                          date.

Right to Renew:           Tenant will have the option to renew for one (1) three
                          (3) year period at $21.50 per square foot ($132,633.50
                          per annum or $11,052.79 per month) with a 180 day
                          prior written notice to Landlord.

Security Deposit:         $ 9,253.50

Permitted Uses:           General office use

Tenant's Proportionate    9.49%
Share:

Base Operating Costs:     2003 Actual

Base Taxes:               2003 Actual

Liability Insurance       $1,000,000 per occurrence
Minimum Limits:           $1,000,000 products and completed operations
                          $1,000,000 personal injury
                          $2,000,000 general aggregate

Broker:                   Insignia/ ESG and T3 Realty Advisors, LLC

<PAGE>

Landlord:                           Tenant:

100 & 200 Foxborough                   Cyberkinetics, Inc.
Boulevard Realty Trust

 BY: /s/ Charles E. Harlfinger         BY: /s/ Tim Surgenor
     ------------------------------       -------------------------------------
    Charles E. Harlfinger, Trustee         Tim Surgenor,
    and not individually                  President and Chief Executive Officer

<PAGE>

      THIS INSTRUMENT IS A LEASE, dated as of the Execution Date stated in
Exhibit 1, in which Landlord and Tenant are the parties named in said Exhibit
and which relates to space in the Building. The parties to this instrument
hereby agree with each other as follows:

      1. REFERENCE DATA: All Exhibits and Riders (if any) attached to this Lease
are hereby incorporated herein and made a part hereof.

      2. LEASE ON PREMISES APPURTENANT RIGHTS. Landlord hereby demises and lease
to Tenant for the Term of this Lease and upon the terms and conditions
hereinafter set forth, and Tenant hereby accepts from Landlord, the Premises
described in Exhibit 1 and substantially as shown on Exhibit 2. Excepted and
excluded from the Premises are the ceiling, floor, perimeter walls and exterior
windows, except the inner surfaces of each thereof, but the entry doors (and
related glass and finish work) to the Premises are a part thereof; and Tenant
agrees that Landlord shall have the right to the Premises (but in such manner so
as to minimize interference with Tenant's use of the Premises) utility lines,
pipes, equipment and the like, in, over, and through the Premises. Tenant shall
install and maintain, as Landlord may require, proper access panels in any hung
ceiling or walls may be installed by Tenant in the Premises to afford access to
any facilities above the ceiling or within or behind the walls. Tenant shall
have, as appurtenant to the Premises, the non-exclusive right to use, and permit
its invitees to use, in common with others, the common areas of the Property
including, the common walkways, driveways and parking areas located on the
Property, the entrances, exits, lobbies, vestibules, elevators, stairways,
halls, water, bubblers and lavatories of the Building outside the Premises the
common walkways and driveways necessary for access to the Building, the common
toilets and corridors of such floor; but such right shall always be subject to
reasonable rules and regulations from time to time established by Landlord
pursuant to Section 24 hereof and to the right of Landlord to designate and
change from time to time the areas so to be used, provided that such changes do
not materially adversely affect Tenant's use and enjoyment of the Leased
Premises and its appurtenant rights hereunder.

      3. BASIC RENT. Tenant agrees to pay to Landlord, commencing on the
Commencement Date without offset, abatement (except as provided in Section 20),
deduction or demand, the Basic Rent set forth in Exhibit 1. Such Basic Rent
shall be payable in equal monthly installments, in advance, on the first day of
each calendar month during the term of the Lease, at such address as Landlord
shall from time to time designate by notice. Notwithstanding the foregoing,
Tenant shall pay the first (1ST) month's Basic Rent upon execution of this
Lease. In the event that any installment of Basic Rent is not paid within five
(5) days after when due, Tenant shall pay, in addition to any charges under
Section 30, at Landlord's request an administrative fee equal to 1% of the
overdue payment, as additional rent. Basic Rent for any partial month shall be
prorated on a daily basis.

      4. SECURITY DEPOSIT. Tenant agrees that the security specified in Exhibit
1 will be paid upon execution of this Lease, and that Landlord shall hold the
same throughout the Term of this Lease as security for the performance by Tenant
of all obligations on the part of Tenant hereunder. Landlord shall have the
right from time to time, without prejudice to any other remedy Landlord may have
on account thereof, to apply such deposit, or any part thereof, to Landlord's
damages arising from, or to cure, any default to Tenant under this Lease. If
Landlord shall so apply any or all of such deposits, Tenant shall immediately
deposit with Landlord the amount so applied to be held as security hereunder.
While Landlord holds such deposit, Landlord shall have no obligation to pay
interest on the same and shall have the right to commingle the same with
Landlord's other funds.

      5. COMMENCEMENT DATE. The Commencement Date shall be as stated on Exhibit
1.

<PAGE>

      6. PREPARATION OF THE PREMISES.

      (a.) Landlord agrees to perform the work ("Landlord's Work") described on
Exhibit 1 to prepare the Premises for Tenant's occupancy, although Landlord
reserves the right to make minor changes and substitutions of similar quality as
the exigencies of the job may require. Landlord shall endeavor to substantially
complete Landlord's Work June 1, 2003. The Premises shall be deemed
substantially complete when the same are ready for occupancy by Tenant as to the
Premises only minor, punch-list items that can be completed within thirty (30)
days remain for Landlord to complete. Notwithstanding the foregoing, Landlord
shall not be responsible for delays in substantially completing Landlord's Work
caused, in whole or in part, by events beyond Landlord's reasonable control or
by Tenant or its agents, employees or contractors and, in the event of such
delays caused by Tenant or its agents, employees or contractors, the
Commencement Date shall be deemed to have occurred on the date that the Premises
would have been ready for Tenant's occupancy but for such delay. In the event
that Landlord is unable to substantially complete Landlord's Work by the date
(the "Outside Completion Date") which is sixty (60) days after the Commencement
Date set forth on Exhibit 1, due to Tenant's delays at any time after the
Outside Completion Date and thereupon this Lease shall terminate without further
obligation or liability on the part of either party, except that Tenant shall
pay to Landlord the damage suffered by Landlord by reason of such Lease
termination, including without limitation, Landlord's expenses incurred in
connection with the preparation of the Premises, and brokerage and legal fees.
Tenant shall have no claim against Landlord, and Landlord shall have no
liability to Tenant, for Landlord's failure so to complete Landlord's Work by
the Commencement Date, but Landlord shall prosecute Landlord's Work to
completion with due diligence.

      (b.) Tenant shall have no claim that Landlord has failed to perform any of
Landlord's Work, unless Tenant shall have given Landlord written notice, not
later than the end of the second full calendar month beginning after the
Commencement Date, of respects in which Landlord has not performed Landlord's
Work.

      7. USE. Tenant agrees that it shall use and occupy the Premises during the
Term only for Permitted Uses expressly described in Exhibit 1 and for no other
purposes. Tenant shall, in its use of the Premises, comply with the requirements
of all applicable governmental laws, rules and regulations (including, without
limitation, the requirements of all federal, state and local laws, rules and
regulations concerning environmental, health and /safety matters) and shall
obtain (and keep in full force and effect) all required license and permits
therefor. Tenant shall not permit any use of the Premises which will make
voidable any insurance on the Property, or on the contents of the Property, or
which shall be contrary to any law or regulation from time to time established
by the New England Fire Insurance Rating Association, or any similar body
succeeding to its power. Tenant shall on demand reimburse Landlord for all extra
insurance premiums caused by Tenant's use of the Premises. If any governmental
license or permit shall be required for the proper and lawful conduct of
Tenant's business, Tenant at its expense shall duly procure and thereafter
maintain and comply with such license or permit and submit the same to
inspection by Landlord.

      8. INSTALLATIONS AND ALTERATIONS BY TENANT. Tenant shall make no
alterations, addition or improvements ("Alterations") in or to the Premises
without the Landlord's prior written consent in each instance, which consent
shall not be unreasonably withheld, conditioned or delayed. All Alterations
shall be performed by a contractor(s) approved by Landlord. Each such
contractor(s) shall carry commercial general liability insurance, and such other
insurance (including, without limitation, workers' compensation insurance
covering the employees of all such contractor(s)), in such form, amounts and
with such carriers as are reasonably acceptable to Landlord, and under which
Landlord and Landlord's managing agent (and such other persons as Landlord may
designate from time to time) are named as insureds. All Alterations shall
conform to the plans and specifications submitted to Landlord for

<PAGE>

approval. Any deviations to such plans and specifications shall require
Landlord's prior written consent, which consent shall not be unreasonably
withheld, conditioned or delayed. Tenant shall pay to Landlord from time to time
upon demand any and all reasonable cost and expenses incurred by Landlord in
connections with the review and supervision of any Alterations (including,
without limitation, the cost and expense of Landlord's architects and
engineers). All Alterations shall be performed in a good and workmanlike manner
and in compliance with all applicable laws and other governmental requirements,
and Tenant shall obtain (and comply with) any and all permits and licenses
required thereof. Any such Alterations shall become part of the Premises and the
property of Landlord, unless Landlord requests Tenant to remove the same at the
expiration of Term of the Lease, in which event Tenant shall remove the same and
repair any damage caused by such removal. Tenant shall promptly remove any
mechanic's lien that may be filed against the Property based upon any such work
in or on the Premises. If Tenant shall make or cause to be made any Alteration
to the Premises which shall result in an increase in the real estate taxes upon
the Building, then Tenant shall pay the entire increase in such taxes
attributable to such Alterations.

      9. ASSIGNMENT AND SUBLETTING. Tenant covenants and agrees not to assign
this Lease or to mortgage, pledge, encumber or sublet the Premises or any part
thereof without Landlord consent thereto, which shall not be unreasonably
withheld, conditioned, or delayed. Any consent by Landlord to a particular
assignment, mortgage, pledge, encumbrance, or subletting shall not in any way
diminish the prohibition stated in the preceding sentence. No assignment or
subletting hereunder nor Landlord's consent thereto shall receive Tenant from
its obligation under this Lease and Tenant shall remain fully primarily liable
therefor. No assignment or subletting shall affect Permitted Uses.

      10. REPAIRS AND MAINTENANCE BY LANDLORD. Landlord shall make all repairs
necessary to keep the roof of the Building leak-free and shall keep the
structural support elements and the exterior cladding of the Building and the
Building systems (including, without limitation, the Building electrical,
plumbing, mechanical, heating, ventilating and air conditioning systems) common
areas in good condition, order and repair, damage resulting from any act or
omission of Tenant or its agents, contractors and employees only expected; and
Landlord shall keep all lawns and landscape areas of Property watered,
fertilized and trimmed and shall provide for removal of snow and ice from, and
sanding of, the sidewalks, parking lots, access driveways and walkways as
necessitated by weather conditions and shall provide for parking lot lighting
and shall repair and maintain the parking lot and the lighting serving the same
as necessary. Landlord's obligation under this Section 10 shall be subject to
the provisions of Section 20. Landlord shall not be liable for any failure to
make repairs which Landlord has undertaken to make under this Lease, unless
Tenant has given notice to Landlord of the need to make such repairs, and
Landlord has failed to commence to make such repairs within a reasonable time
after receipt of such notice, or fails to proceed with reasonable diligence to
complete such repairs.

      11. REPAIRS AND MAINTENANCE BY TENANT. Tenant shall (i) make all repairs
and replacements as necessary to keep the Premises, including, without
limitation, all interior glass, in as good condition and repair as the same are
in at the commencement of the Term, repairs which are the obligation of Landlord
under Section 10 only excepted, and (ii) keep and maintain all portions of the
Premises in a clean and orderly condition, free of accumulation of dirt,
rubbish, and other debris. Notwithstanding the provisions of Sections 10 and 20,
Tenant shall be responsible for the cost of repairs which may be made necessary
by reason of damages to the Building caused by any act of neglect of Tenant or
its agents, employees, contractors or invitees (including any damage by fire or
any other casualty arising therefrom).

      12. UTILITIES. Tenant shall pay the amount stated on Exhibit 1 for its use
of electricity. Tenant shall, at its own cost and expense, arrange and pay for
other services provided to the Premises, including, without limitation,
telephone and computer service.

<PAGE>

      13. BUILDING SERVICES. Landlord shall, on weekdays (except Building
holidays) from 7:00 a.m. to 6:00 p.m. and on Saturdays (except Building
holidays) from 9:00 a.m. to l:00 p.m., furnish heating and cooling as normal
seasonal changes may require to provide reasonably comfortable space temperature
and ventilation for occupants of the Premises and the common areas of the
Building under normal business operation. If Tenant shall require air
conditioning or heating at any time other than such days or during such hours,
Landlord may, upon Tenant's reasonable request, furnish such service and Tenant
shall pay such charges thereof as may from time to time be in effect, allocated
among multiple overtime users where applicable. Tenant shall not introduce into
the Premises personnel or equipment which overloads the capacity of the Building
HVAC system or in any other way interferes with such system's ability to perform
adequately its proper functions, provided, however, if Tenant shall violate the
foregoing, Landlord may, at its option, elect to provide the supplementary
systems or otherwise take steps to cure such violation, at Tenant's sole cost
and expense. Landlord shall also provide:

      (a.) Water lavatory and drinking purposes at temperatures and otherwise as
supplied by the Town of Foxborough or other water provider.

      (b.) Cleaning and janitorial services to the Premises (provided that same
are kept in order by Tenant) and common areas of the Building in accordance with
the cleaning standards set forth in Exhibit 3 attached hereto.

      (c.) 24-hour access to the Premises, subject to reasonable security
procedures and restrictions based on emergency conditions.

Landlord shall have the right to interrupt, curtail, stop or suspend the
operation of the Building's plumbing and electrical systems and any other
Building services or utilities in the case of emergency or accident, or for the
purpose of making any repairs, alterations, or improvements to the Building
Premises, or in the case of any other event beyond Landlord's reasonable
control. There shall be no diminution or abatement of rent or other charges
hereunder, nor shall this Lease be affected or any of Tenant's obligations
hereunder reduced, by reason of, and Landlord -shall have no responsibility or
liability for, any such interruption, etc., except that Landlord shall exercise
reasonable diligence to eliminate the cause of same.

      14. ESCALATION.

      (a.)  DEFINITIONS. For the purpose of this Section 14, the following terms
            have the following respective meanings:

            (i.)  YEAR: each calendar year in which any part of the Term of this
                  Lease shall fall.

(ii.) TAX PERIOD: Each fiscal/tax year in which any part of the term of this
      Lease shall fall.

            (iii.) OPERATING COSTS: The average of all costs and expenses
                  incurred (or deemed incurred under the next succeeding
                  paragraph) by Landlord with respect to the administration,
                  repair, maintenance, replacement, alteration, improvement,
                  operation, management, cleaning and servicing of the Building
                  and Property, and the portion of such costs and expenses
                  incurred by Landlord with regard to the common areas of the
                  complex or park of which the Building is a part which is
                  fairly allocable to the Building and the Property, and
                  including, without limitation, the following: any and all cost
                  and expenses incurred by Landlord for heat, ventilation and
                  air conditioning, electricity, water and sewer use charges,

<PAGE>

                  administrative and management services (including, without
                  limitation, professional services and management fees, but
                  excluding all leasing expenses and any rent for a management
                  office), performance of Landlord's obligations under Section
                  10, insurance, payroll and benefits of maintenance and
                  management staff, but excluding salaries for all personnel at
                  or above the level of vice president, and pest control
                  services, but excluding Taxes and special services rendered to
                  other tenants. In the event that during all or any portion of
                  any year the Building is not fully rented and occupied,
                  Landlord may elect to make appropriate adjustments in
                  Operating Costs for such year to determine Operating Costs
                  that would have been paid or incurred by Landlord had the
                  building been fully rented and occupied, and the amount so
                  determined shall be deemed to have been the Operating Costs
                  for such year.

      (IV.) TAXES: The real estate and other taxes, levies and assessments
            imposed upon the Building and the Property and upon any personal
            property of Landlord solely used in the operation thereof;
            betterment assessment apportioned over the longest payment period
            permitted by law (including interest thereon); charges, fees and
            assessments for police, fire and other governmental services or
            purported benefits to the Building; service or user payments in lieu
            of taxes; and any and all other taxes, levies, betterments,
            assessments and charges arising from the ownership, leasing,
            operating, use or occupancy of the Building or based upon rental
            derived therefrom, which are or shall be imposed by National, State,
            Municipal or other authorities. As of the Execution Date, Taxes
            shall not include any income or profit tax. provided, however, that
            any tax, excise, fee, levy, charge or assessment, however described,
            that may in the future be levied or assessed as a substitute for or
            in addition to (in while or in part) any tax, levy or assessment
            which would otherwise constitute Taxes, whether or not now customary
            or in the contemplation of the parties of the Execution Date of this
            Lease, shall constitute Taxes, but only to the extent calculated as
            if the Building and the Property were the only real estate owned by
            Landlord. Taxes shall also include reasonable expenses of tax
            abatement or other proceeding contesting of levies.

      (V.)  BASE OPERATING COSTS: the amount set forth in Exhibit 1.

      (VI.) BASE TAXES: The amount set forth in Exhibit 1.

      (IX.) ESCALATION CHARGES: Tenant's Payments for escalations in Operating
            Costs and Taxes as set forth in Section 14(b)(i), (ii), and (iii)
            below.

      (X.)  TENANT'S PROPORTIONATE SHARE: The fraction or percentage set forth
            on Exhibit 1, being the Premises Rentable Area divided by the
            building Rentable Area.

(b.)  TENANT'S PAYMENTS OF ESCALATION CHARGES:

      (i.)  If Operating Costs in any Year exceed Base Operating Costs, Tenant
            shall pay to Landlord the product of (x) the amount by which
            Operating Costs for such Year exceed Base Operating Costs,
            multiplied by (y) Tenant's Proportionate Share, such amount to be
            apportioned for any Year in which the Commencement Date occurs or
            the Term ends.

      (ii.) If taxes in any Tax Period exceed Base Taxes, Tenant shall pay to
            Landlord the product of (x) the amount by which Taxes for such Tax
            Period Exceed Base Taxes, multiplied by (y) Tenant's Proportionate
            Share, such amount to be apportioned for any Tax Period in which the
            Commencement Date occurs or the Term ends.

<PAGE>

     (iii.) Escalation Charges shall be due when billed by Landlord. In
            implementation but without limitation, of the foregoing, Tenant
            shall, make monthly estimated payments to Landlord on account of
            Escalation Charges, payable at the time and in the fashion herein
            provided for the payment of Basic Rent. The monthly amount to be
            paid to Landlord shall be sufficient to provide Landlord (x) by the
            end of each Year, a sum equal to Tenant's required payments, as
            estimated by Landlord from time to time during each tax Period, on
            account of Escalation Charges for Taxes for such Year, and (y) by
            end of each tax period, a sum equal to Tenant's required payments,
            as estimated by Landlord from time to time during each Tax Period,
            on account of Escalation Charges for Taxes for such Tax Period.
            Landlord shall have the right from time to time during the course of
            any Year and/or Tax Period to adjust the amount of Tenant's
            estimated payment based upon the most recent data with respect to
            Escalation Charges then available (e.g. Landlord's receipt of a new
            tax bill). After the end of each Year, Landlord shall submit to
            Tenant a reasonably detailed accounting of Operating Costs for such
            Year, and Landlord shall certify to the accuracy thereof. If
            estimated payments previously made by Tenant on account of
            Escalation Charges for such Year exceed Tenant's required payment on
            account thereof for such Year, according to such statement,
            Landlord, shall credit the amount of overpayment against subsequent
            obligations of Tenant with respect to Basic Rent or Escalation
            Charges (or refund such overpayment if the Term has ended and Tenant
            has no further obligation to Landlord); but, if estimated payments
            previously made by Tenant on account of Escalation Charges for such
            Year are less than the required payments on account thereof for such
            Year, Tenant shall make payment of such deficiency to Landlord
            within thirty (30) days after notice from Landlord. Landlord shall
            have the same rights and remedies for nonpayment by Tenant of any
            payment due on account of Escalation Charges as Landlord has
            hereunder for the failure of Tenant to pay Basic Rent. Landlord's
            and Tenant obligations with respect to adjusting Escalation Charges
            for the Year, and Tax Escalation Charges for the Tax Period, in
            which the Term of this Lease ends shall survive the expiration or
            sooner termination of this Lease.

c. ABATEMENT OF TAXES. If Landlord shall receive any tax refund or reimbursement
of Taxes or sum in lieu thereof with respect to any Tax Period, then out of any
balance remaining thereof after deducting Landlords expenses reasonably incurred
in obtaining such refund, Landlord shall pay to Tenant, provided there does not
then exist a default of Tenant hereunder, an amount equal to such refund or
reimbursement or sum in lieu thereof (exclusive of any interest) multiplied by
Tenants Proportionate Share; provided, however, that in no event shall Tenant be
entitled to receive more than the payments made by Tenants pursuant to Section
14(b) on account of Tax Escalation Charges for such Tax Period or to receive any
payment or abatement of basic Rent.

      15. WAIVER OF SUBROGATION. Neither Landlord (including, for purposes
hereof, Landlord's managing agent) not Tenant shall be liable to the other party
or to any insurer of such other party with respect to any loss or damage to the
real or tangible personal property of such other party resulting from or caused
by any peril which is covered by fire, theft, vandalism, malicious mischief,
water damage and /or extended coverage insurance (whether or not such insurance
is carried by other party) or which is in fact insured against by the party
suffering such loss hereto or any of its or their agents, servants, invitees or
contractors. The parties hereto shall each procure an appropriate clause in, or
endorsement on, any such insurance policy covering the Premises, the Building
and/or personal property, fixtures and equipment located thereon or therein,
pursuant to which the insurer waives subrogation or consents to waiver of right
of recovery as provided in the preceding sentence.

<PAGE>

      16. TENANT'S INDEMNITY. Tenant agrees to defend, indemnify and save
harmless Landlord and Landlord's agents and employees from and against all loss,
liability, damage, cost, expense (including, without limitation, reasonable
attorney's fees) and claims of whatever nature arising from Tenant's breach of
any term, covenant, provision or condition of this Lease on Tenant's part to be
performed or: (i) from any accident, injury or damage whatsoever to any person,
or to the property of any person, in or about the Premises (unless and to the
extent such accident, injury or damage is caused by the negligence or willful
misconduct of Landlord or those for whom Landlord is legally responsible): or
(ii) from any accident, injury or damage to persons or property occurring
outside of the premise but in the property, where such accident, damage or
injury results or is claimed to have resulted from an act or omission on the
part of Tenant or Tenant's agents, employees invitees or contractors.

      17. LIABILITY INSURANCE. Tenant agrees to maintain throughout out the term
of this Lease a policy of commercial general liability insurance (with broad
form contractual liability coverage) in such form, amounts and with carrier
reasonably acceptable to Landlord, and under which Landlord and Landlord's
managing agent (and such persons as Landlord may designate by notice to Tenant
from time to time) are named as additional insureds. The minimum amounts of
coverage shall be set forth in Exhibit 1. Each such policy shall be
non-cancelable and non-amenable with respect to Landlord and Landlord's managing
agent (and Landlord's said designees) without thirty (30) days' prior to each
such party: and a duplicate original or certificate thereof shall be delivered
to Landlord prior to the first day upon which Tenant shall enter the Premises or
any thereof. Certificates of renewal policies shall be delivered to Landlord at
least thirty (30) days prior to the expiration of the each expiring policy.

      18. TENANT'S RISK. Tenant agrees to use and occupy the Premises at
Tenant's own risk. Tenant shall maintain insurance in respect of its personal
property, business fixtures and leasehold improvements, and Landlord shall have
no responsibility or liability for any loss of or damage to any of the same, or
for any inconvenience, annoyance, interruption or injury to business arising
from Landlord's making repairs or changes which Landlord is permitted by this
Lease, or required by law, to make in or to any portion of the Premises or other
sections of the Park Tenant agrees that Landlord shall not be responsible or
liable to Tenant, or to those claiming by, through or under Tenant, for any loss
or damage that may be occasioned by or through the acts or omissions of persons
occupying adjoining premises or any part of the Premises to or connecting with
the Premises otherwise.

      19. LANDLORD'S ACCESS RIGHTS. Landlord shall have the right to enter the
Premises at all reasonable hours upon reasonable notice for the purpose of
inspecting or making repairs to the same, and to show the Premises to
prospective or existing mortgages, purchasers or, in the final year of the Term
(as may have been extended), tenants of any part of the property.

      20. FIRE, EMINENT DOMAIN, ETC. If the Premises shall incur minor damage by
reason of fire or other casualty (other than as a result of Tenant's fault or
negligence) or by reason of a taking by eminent domain. Landlord will restore
the Premises (excluding any improvements installed in the Premises by or at the
expense of Tenant) to proper condition for Tenant's use and occupancy as
speedily as possible to the extent of the available insurance proceeds or
condemnation awards, as the case may be. If any part of the Premises, the
Building and/or the Property shall, in Landlord's reasonable opinion, incur
substantial damage by reason of such fire, other casualty or taking, or the
insurance proceeds or condemnation award is inadequate. Landlord shall have the
right to terminate the Lease by notice to Tenant within sixty (60) days
following such event and if Landlord does not exercise such right, Landlord
shall promptly repair the Premises, Building and Property. If the Premises are
rendered unusable by the damage or taking, Tenant shall not be liable to pay
Basic Rent, additional rent or Escalation Charges (or a proportionate part
thereof, as appropriate) if and to the extent and for as long as the Premises
remain unusable. If and to the extent Premises are usable, Tenant must continue
to pay Basic Rent. Landlord hereby reserves and excepts, and Tenant hereby
grants and assigns to Landlord, all

<PAGE>

rights to recover for damages to the Property and Leasehold interest hereby
created, and to compensation accrued or hereafter to accrue by reason of such
fire, casualty or taking.

      21. TENANT'S DEFAULT. Tenant shall be in default under this Lease in the
event that Tenant (a) shall fail to make any payment of money (including,
without limitation, Basic Rent and Escalation Charge) when it is due hereunder
and such failure shall continue for five (5) days after notice from Landlord to
Tenant, or (b) shall fail or neglect to perform or observe any other covenant or
obligation under this Lease and Tenant shall fail to remedy the same within
thirty (30) days after notice from Landlord to Tenant specifying such failure or
neglect (provided, however, that if such failure or neglect is of such nature
that Tenant cannot reasonably remedy the same within such thirty (30) day
period. Tenant shall have such additional period of time to remedy the same if
Tenant shall commence such remedy within such thirty (30) day period and
thereafter diligently and continuously prosecute such remedy to completion), or
(c) shall commence reorganization, bankruptcy or insolvency proceedings of, in
case any such proceedings are brought against Tenant, if the same are not
dismissed within thirty (30) days or if any assignment shall be made of Tenant's
property of the benefit or creditors. If Tenant shall be in default under this
Lease, Landlord shall have the all right and remedies as are available at law or
in equity. Such rights and remedies shall include, without limitation, the right
to evict Tenant, take exclusive possession of the Premises, continue to collect
Basic Rent, Escalation Charges and other charges, terminate the Lease, obtain a
judgement for all damages that might flow from a breach or termination of this
Lease, re-let the Premises or any part thereof and make any repairs or
alterations to the Premises. Without limiting the foregoing, in the event of any
termination of this Lease as provided in this Section 21, Tenant shall pay the
Basic Rent, Escalation Charges and all other sums payable hereunder up to the
time of such termination, and in addition shall pay to Landlord as damages, at
the election of Landlord, either:

      (a.) The Basic Rent, Escalation Charges and all other sums which would
have been payable hereunder if such termination has not occurred, at the times
and in the manner thereof specified herein, less the net proceeds, if any,
re-letting of the Premises, after deducting all expenses in connection with such
re-letting, including, without limitation, all repossession costs, brokerage
commissions, legal expenses, attorney' fees, advertising expense and alteration
cost;

                                       OR

      (b.) The amount by which at the time of the termination of this Lease (or
at any time thereafter upon demand if Landlord shall initially elected damages
under clause (a) above), the basic Rent, Escalation Charges and all other sum
which would have been payable hereunder from the date of such termination of
demand (assuming that, for the purpose of this clause (b) annual payment by
Tenant on account of Escalation Charges would be the same as the payment
required for the 12-month period immediately preceding the date of such
termination or demand) for what would have been the then remaining Term of this
Lease if same had remained in effect, exceeds the then fair rental value of the
Premises for the same period.

Tenant shall pay Landlord's cost of enforcing this Lease, including without
limitation, reasonable attorneys' fees and cost.

      22. LANDLORD'S DEFAULT. Landlord shall in no event be in default in the
performance of any of Landlord's obligation hereunder unless and until Landlord
shall have failed to perform such obligations within thirty (30) days, or such
additional time as is reasonably required to correct any such default, other
notice by Tenant to Landlord and any Mortgagee (as herein defined) specifying
wherein Landlord has failed to perform any such obligations. As used herein, the
term "Mortgagee" shall mean

<PAGE>

the holder(s) of any mortgage(s), and/or the ground lessor under any ground
lease, covering the Building, of whose name(s) and address(s) Tenant shall have
been given notice.

      23. LANDLORD'S LIABILITY. (a.) Tenant specifically agrees to look solely
to Landlord's then interest in the Property at the time owned for recovery of
any judgment from Landlord; it being specifically agreed that in no event shall
Landlord (original or successor), or any of the officers, trustees, directors,
partners, beneficiaries, stockholders or other principals or representatives,
and the like, disclosed or undisclosed, thereof, ever be personally liable for
any such judgment, or for any other liability or for the payment of any monetary
obligation to Tenant. In no event shall Landlord (original or successor) or any
such officers, etc., as aforesaid, ever be liable to Tenant for any indirect or
consequential damages suffered by Tenant from whatever cause.

      (b.) With respect to any services or utilities to be furnished by Landlord
to Tenant or any other obligations to be performed by Landlord under this Lease,
Landlord shall in no event be liable (beyond an abatement of Basic Rent and
Escalation Charges where provided for herein) for failure to furnish or perform
the same when prevented from doing so by reason of force majeure, or for any
cause beyond Landlord's reasonable control, or for any cause due to any act or
neglect of Tenant or Tenant's agent, employees or contractors or any person
claiming by, through or under Tenant.

      (c.) In the event of any transfer of Landlord's interest in the Property,
the party making such transfer shall upon such transfer and the transfer of the
Security Deposit to Landlord's successor in interest be entirely freed from the
performance and observance of all covenants and obligations hereunder, Tenant
agreeing to look solely to the holder of the Landlord's interest in this Lease
from time to time, subject to the limitations set forth in paragraph (a) above.

      24. RULES AND REGULATIONS. Tenant shall abide by reasonable rules and
regulations from time to time established by the Landlord for the Building.
Landlord agrees to use reasonable efforts to insure that any such rules and
regulations are uniformly enforced, but Landlord shall not be liable to Tenant
for violation of the same by any other tenant or occupant of the Building, or
persons having business with them. In the event that there shall be any conflict
between such rules and regulations and the provisions of this Lease, the
provisions of the Lease shall control. The current rules and regulations are
attached to this Lease as Exhibit 4.

      25. NOTICES. Whenever, by the terms of this Lease, notices, requests,
consents and approvals shall or may be given either to Landlord or to Tenant,
they shall be in writing and shall be delivered in hand or sent by express,
registered or certified mail, postage prepaid:

      If intended for Landlord addressed to Landlord's Original Address as
      stated in Exhibit 1 (or such other address or addresses as may from time
      to time hereafter be designated by Landlord by like notice).

      If intended for Tenant, addressed to Tenant at Tenant's Original Address
      as stated in Exhibit 1 until the Commencement Date and thereafter to the
      Premises (or to such other address or addresses as may from time to time
      hereafter be designated by Tenant by like notice).

All such notices shall be effective (i) when hand-delivered or (ii) if mailed,
when deposited in the United States mail within the Continental United States,
provided that the same are received in ordinary course at the address to which
the same were sent. Notices may be sent by a party's attorney or managing agent.

      26. HEADINGS. The section and paragraph headings throughout this
instrument are for convenience and reference only, and shall not be used to
construe this Lease.

<PAGE>

      27. RIGHTS OF MORTGAGEE OR GROUND LESSOR. Tenant acknowledges and agrees
that this Lease shall be subject and subordinate to any mortgage or ground lease
(and to any renewals, modification, amendments, extensions, replacements and
substitutions of or for such mortgage or ground lease) from time to time
encumbering the Premises, whether executed and delivered prior to or subsequent
to the date of this Lease, if the holder of such mortgage or ground lease shall
so elect, provided that, as to future mortgages or ground leases, such lenders
or lessees agree not to disturb Tenant's rights under this Lease. If this Lease
is subordinate to any mortgage or ground lease the holder (or successor) Tenant
shall attorn to such holder and this Lease shall continue in full force and
effect between such holder (or successor) and Tenant. Tenant agrees to execute
such instruments of subordination or attornment in confirmation of the foregoing
agreement as such holder (or successor) may request.

      28. ESTOPPEL CERTIFICATE. Tenant shall at any time and from time to time
within ten (10) days of Landlord's request, execute and deliver an estoppel
certificate affirming this Lease, indicating whether there are any defaults
hereunder, and addressing such other matters as Landlord, Landlord's lender(s)
or prospective purchaser(s) or investors may reasonably require.

      29. PURPOSELY OMITTED

      30. REMEDYING DEFAULTS. Landlord shall have the right, but not the
obligation to pay such sums or take such action as may be necessary or
appropriate by reason of the failure or neglect of Tenant to perform any of the
provisions of this Lease, and in such event, Tenant agrees to reimburse Landlord
upon demand for all costs and expense so incurred by Landlord, together with
interest thereof at a rate equal to 10% per annum (or at any applicable lesser
maximum legally permissible rate for debts of this nature), as additional rent.
Any payment of Basic Rent, Escalation Charges or other sums payable hereunder
not paid when due shall bear interest at the rate as aforesaid from the date
thereof an shall be payable on demand by Landlord, as additional rent.

      31. HOLDING OVER. Any holding over by Tenant after the expiration or
sooner termination of the Term of this Lease shall be treated as a daily at
sufferance at a rate equal to one and 50/100 (1.50) times the sum of (i) Basic
Rent then in effect plus (ii) Escalation Charges and all other charges herein
provided for (prorated on a daily basis). Tenant shall also pay to Landlord all
damages, direct and/or indirect (including without limitation, the loss of a
tenant and of rental income) sustained by reason of any such holding over.
Otherwise, such holding over shall be on the terms and conditions set forth in
this Lease as far as applicable.

      32. SURRENDER OF PREMISES. Upon the expiration or earlier termination of
the Term of this Lease, Tenant shall peaceably quit and surrender to Landlord
the Premises in neat and clean condition and in good order, condition and repair
and otherwise in the same conditions as Tenant is required to maintain the
Premises under Section 11 above, excepting only reasonable wear and tear and
damage by fire or other casualty. Tenant shall remove all of Tenant's property
and, if and to the extent specified by Landlord (but not otherwise), all
Alterations made by Tenant and all partitions wholly within the Premises unless
initially by Landlord in preparing the Premises for Tenant's occupancy; and
Tenant shall repair any damages to the Premises or the Building caused by such
installation or removal.

      33. PURPOSELY OMITTED

      34. BROKERAGE. Tenant warrants and represents that Tenant has dealt with
no broker in connection with the consummation of this Lease other than the
Broker(s) listed in Exhibit 1. In the event of any brokerage claims against
Landlord predicated upon prior dealings with Tenant, Tenant agrees to

<PAGE>

defend the same and indemnify Landlord against any such claim (except any claim
by the Broker(s) listed in Exhibit 1).

      35. GOVERNING LAW. This Lease shall be governed by and construed in
accordance with the law of the Commonwealth of Massachusetts.

      36. WAIVER.

      (a.) Failure on the part of either party to seek redress for violation of
or to insist upon the strict performance of any covenant or condition of this
Lease shall be deemed a waiver of such violation. Further, no waiver of any time
of any of the provisions hereof Landlord or Tenant shall be construed as a
waiver at the subsequent time of the same provisions. The receipt by Landlord of
rent with knowledge of the breach of any covenant of this Lease shall not be
deemed to have been a waiver of such breach by Landlord. The consent or approval
of Landlord or Tenant to or of any action by the requiring such consent or
approval shall not be construed to waive or render unnecessary Landlord's or
Tenant consent or approval to or of any subsequent similar act by the other.

      (b.) No Payment by Tenant, or acceptance by Landlord, of a lesser amount
than shall be due from Tenant to Landlord shall be treated otherwise than as a
payment on account of the earliest installment of any payment due from Tenant
under the prison hereof. The acceptance by Landlord of a check for a lesser
amount with an endorsement or statement thereon, or upon any letter accompanying
such check, that such lesser amount is payment in full, shall be given no
effect, and Landlord may accept such check without prejudice to any other rights
or remedies which Landlord may have against Tenant.

      37. COVENANT OF QUIET ENJOYMENT. Tenant, subject to the terms and
provisions of this Lease on payment of the Basic Rent, Escalation Charges and
all other sums payable hereunder, and observing, keeping and performing all of
the other terms and provisions of this Lease on Tenant's part to be observed,
kept and performed, shall lawfully, peaceably and quietly have, hold, occupy and
enjoy the Premises during the Term hereof, without hindrance or ejection by any
person lawfully claiming under Landlord to have title to the Premises superior
to Tenant; the foregoing covenant of quiet enjoyment is in lieu of any other
covenant, express or implied.

      38. INVALIDITY OF PARTICULAR PROVISIONS. If any term or provision of this
Lease, or the application thereof to any person or circumstances, shall, to any
extent, be invalid or unenforceable, the remainder of this Lease, or the
application of such term or provision to persons or circumstances other than
those as to which it is held invalid or unenforceable, shall not be affected
thereby, and each term and provision of this Lease shall be valid and be
enforced to the fullest extent permitted by law.

      39. PROVISION BINDING, ETC. Except as herein otherwise provided, the terms
hereof shall be binding upon and shall inure to the benefit of the successors
and assigns, respectively, of Landlord and Tenant and, if Tenant shall be an
individual, upon and to his heirs, executors, administrators, successors and
assigns. Each term and each provision of this Lease to be performed by Tenant
shall be construed to be both a covenant and a condition. The reference
contained to successors and assigns of Tenant is not intended to constitute a
consent to assignment by Tenant, but has reference only to those instances in
which Landlord may later give consent to a particular assignment.

      40. RECORDING. Tenant agrees not to record this Lease, but each party
hereto agrees on the request of the other, to execute a memorandum or notice of
lease in form recordable and complying with applicable law and reasonably
satisfactory to Landlord's attorneys. In no event shall such document set forth
the rent or other charges payable by Tenant under this Lease; and any such
document shall

<PAGE>

expressly state that is executed pursuant to the provisions contained in this
Lease and is not intended to vary the terms and conditions of this Lease.

      IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease to be duly
executed, under seal, by persons hereunto duly authorized, in multiple copies,
each to be considered an original hereof, as of the Execution Date stated in
Exhibit 1.

Landlord:                               Tenant:

100 & 200 Foxborough Boulevard          Cyberkinetics, Inc.
Realty Trust

By:/s/Charles E. Harlfinger             By:/s/Tim Surgenor
   ------------------------------          -------------------------------------
   Charles E. Harlfinger, Trustee          Tim Surgenor,
   and not individually                    President ana Chief Executive Officer

<PAGE>

                                    EXHIBIT 3

                      FOXBOROUGH BOULEVARD MANAGEMENT, INC.
                            100 FOXBOROUGH BOULEVARD
                              FOXBOROUGH, MA 02035
                            CLEANING SPECIFICATIONS

A.    OFFICE AREAS

1.    DAILY (MONDAY THROUGH FRIDAY, INCLUSIVE, HOLIDAYS EXCEPTED):

      a.    Empty and clean all waste receptacles and remove waste material from
            the Premises.

      b.    Sweep and dust mop all uncarpeted areas using a dust treated mop.

      c.    Vacuum all rugs and carpeted areas.

      d.    Hand dust and wipe clean with treated cloth window sills, door
            ledges, within normal reach.

      e.    Wash clean all water fountains.

      f.    Wipe clean all brass or other bright work.

      g.    Clean glass main entrances to Tenant's suites.

      h.    Upon completion of cleaning, all lights will be turned off and all
            doors locked, leaving the Premises in an orderly condition.

2.    WEEKLY:

      a.    Remove all finger marks from private entrance doors, light switches
            and doorways.

      b.    Vacuum carpet edges.

      c.    Dust all ventilating, air conditioning covers and grills.

3.    MONTHLY:

      a.    All resilient tile floors to be washed or cleaned with dry system
            cleaner.

      b.    Dust wall hangings and vertical surfaces such as walls, doors and
            ducts.

      c.    Dust venetian blinds.

B.    LAVATORIES

1.    DAILY (MONDAY THROUGH FRIDAY, INCLUSIVE, HOLIDAYS EXCEPTED):

      a.    Sweep and damp mop floors.

      b.    Clean all mirrors, powder shelves, dispensers and receptacles,
            bright work, flushometers, piping and toilet seat hinges.

      c.    Wash both sides of all seats.

      d.    Wash and disinfect all basins, bowls, and urinals and walls around
            these units.

      e.    Empty and clean paper towel and sanitary disposal receptacles.

      f.    Remove waste paper and refuse.

      g.    Refill tissue holders, soap dispensers, towel dispensers, sanitary
            dispensers using materials to be furnished by others.

      h.    Dust all partitions and walls.

<PAGE>

      i.    A sanitizing solution will be used in all cleaning.

2.    MONTHLY

      a.    Machine scrub floors.

      b.    Wash all walls and partitions.

C.    COMMON AREAS (MAIN LOBBY, ELEVATOR STAIRWELLS, CORRIDORS, BLDG. EXTERIOR)

1.    DAILY (MONDAY THROUGH FRIDAY, INCLUSIVE, HOLIDAYS EXCEPTED):

      a.    Sweep and wash all floors.

      b.    Wash all rubber mats.

      c.    Empty and clean all ashtrays and waste receptacles.

      d.    Clean elevator, wipe down walls and doors.

      e.    Clean any metal work inside lobby.

      f.    Clean any metal work surrounding building entrance doors.

      g.    Clean entrance glass.

      h.    Spot clean carpet stairs.

      i.    Sweep exterior entrances to building.

2.    WEEKLY:

      a.    In Stairwells: sweep and remove debris, dust walls, and doors, damp
            wipe handrails, vacuum stairs, and wash treads and landings, as
            needed.

      b.    Wash or vacuum elevator floor.

<PAGE>

                                   Exhibit 4

                      RULES AND REGULATION ATTACHED TO AND
                           MADE A PART OF THIS LEASE

      1. The sidewalks, entrances, driveways, passages, courts, elevators,
vestibules, stairways, corridors or halls shall not be obstructed or encumbered
by any Tenant or used for any purposes other than for ingress to and egress from
the demised premises and for delivery of merchandise and equipment in a prompt
and efficient manner using elevators and passageways designated for such
delivery by Landlord. There shall not be used in any space, or in the public
hall of the building, either by any Tenants or others in the delivery or receipt
of merchandise, any hand trucks, except those equipped with rubber tires and
sideguards. At no time is any vehicle to be on the sidewalks or brick entrances.

      2. The water and wash closets and plumbing fixtures shall not be used for
any purpose other than those for which they were designed or constructed and no
sweeping, rubbish, gas, acids, or other substances shall be deposited therein,
and the expense of any breakage, stoppage, or damage resulting from the
violation of this rule shall be borne by the Tenant or their clerks, agents,
employees, or visitors, who have caused it.

      3. No carpet, rug or other article shall be hung or shaken out of any
window of the building; and no Tenant shall sweep or throw or permit to be swept
or thrown from the demised premises any dirt or other substances into any of the
corridors, halls, elevators, or out of the doors or windows or stairway of the
building and Tenant shall not use, keep or permit to be used any foul or noxious
gas or substance in the demised premised in a manner offensive or objectionable
to Landlord or other occupants of the building. There shall be no noise, odors
and/or vibrations permitted that interfere in any way with other Tenants or
those having business therein, nor shall any animals or birds be kept in or
about the building. Smoking or carrying lighted cigars or cigarettes in the
building is prohibited. Tenants and Tenant's employees shall use ashtrays
outside the building, provided by Landlord, for disposal of cigarettes or
cigars. No cigarettes or cigars are to be thrown on the grounds of the building.

      4. No awnings or other projections shall be attached to the outside walls
of the buildings without the prior written consent of the Landlord.

      5. No sign, advertisement, notice or other lettering shall be exhibited,
inscribed, painted or affixed by any Tenant on any part of the outside of the
demised premises or the building or the common area or on the inside of the
demised premises if the same is visible from the outside of the premised without
the prior written consent of Landlord, except that the name of Tenant may appear
on the entrance door of the premises. In the event of the violation of the
foregoing by the Tenant, Landlord may remove same without any liability, and may
charge the expense incurred by such removal to Tenant or Tenants violating this
rule. Interior signs on doors and directory tablet shall be inscribed, painted
or affixed for each Tenant by Landlord in accordance with building standard
signage.

      6. No Tenant shall mark, paint, drill into, or in any way deface any part
of the demised premises or the building of which they form a part. No boring,
cutting or stringing of wires shall be permitted, except with the prior written
consent of the Landlord, and as Landlord may direct. No Tenant shall lay
linoleum, or other similar floor covering, so that the same shall come in direct
contact with the floor of the demised premised, and, if linoleum of other
similar floor covering is desired to be used and

<PAGE>

interlining of builder's deadening felt shall be first affixed to the floor, by
paste or other material, soluble in water, the use of cement or other similar
adhesive material being expressly prohibited.

      7. Any Tenant shall place no additional locks or bolts of any kind upon
any of the doors or windows, nor shall any changes be made in existing locks or
mechanism thereof without Landlord's prior written consent. Each Tenant must,
upon the termination of his Tenancy, restore to Landlord all keys of offices and
toilet rooms, either furnished to, or produce by Tenant and in the event of the
loss of keys, so furnished, such Tenant shall pay to Landlord the cost thereof.

      8. Freight, furniture, business equipment, merchandise and bulky matter of
any description shall be delivered to and removed from the premises only on the
freight elevators and through the service entrances and corridors, and only
during hours and in a manner approved by the Landlord. Landlord reserves the
right to inspect all freight to be brought into the building and to exclude from
the building all freight which violates any of these Rules and Regulations of
the lease of which these Rules and Regulations are a part.

      9. No Tenant shall obtain for use upon the demised premises ice, towel,
and other similar services, or accept barbering or bootblacking services in the
demised premises, except from persons authorized by Landlord, and at hours and
under regulations fixed by Landlord. Canvassing, soliciting and peddling in the
building is prohibited and each tenant shall cooperate to prevent the same.

      10. Landlord reserves the right to exclude from the building between the
hours of 6:00 p.m. and 7:00 a.m., after 1:00 p.m. on Saturdays, and at all hours
on Sundays and legal holidays all persons who do not posses a valid security
access card. Landlord will furnish cards to persons for whom any Tenant requires
same in writing. Each Tenant shall be responsible for all persons for whom he
requests such cards or entrance and shall be liable to Landlord for all acts of
such persons.

      11. Landlord shall have the right to prohibit any advertising
incorporating the Building name and picture by any Tenant which, in Landlord's
opinion, tends to impair the reputation of the building or its desirability as a
building for offices, and upon written notice from Landlord. Tenant shall
refrain from or discontinue such advertising.

      12. Tenant shall not bring or permit to be brought or kept in or not the
demised premises, any inflammable, combustible or explosive fluid, material,
chemical or substance, or any unusual or other objectionable odors to permeate
in or emanate from the demised premises.

      13. As the building contains central air conditioning and ventilation
Tenant agrees to keep all windows closed at all times and to abide by the rules
and regulations issued by the Landlord with respect to such services. If Tenant
requires air conditioning or ventilation after the usual hours, Tenant shall
give 24 hours notice to building management.

      14. In the event that the Tenant requires maintenance services beyond
those required to be provided by Landlord in accordance with Article 13 hereof,
including, without limitation, any services provided by the Building
Superintendent during moves to, from or within the Building, Tenant shall
reimburse Landlord for those services for each hour or fraction thereof, of the
Building Superintendent's time spent on each services, plus five percent (5%).
Payment for such services shall be made following receipt of a billing for such
services.

      15. No commercial vehicles exceeding 1 ton are to enter or exit the
Building and/or the Business Center at Central Street in accordance with the
town of Foxborough.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]